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To Ondrea - you are the Hobbes to my Calvin
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SUMMARY
This thesis develops analytics based tools using operations research and statistical
methodologies to address problems in the domain of cardiovascular disease and blood
pressure management. Cardiovascular disease is the leading cause of death in the
United States and worlwide, and a major component of healthcare costs. Elevated
blood pressure (hypertension) has been shown as a significant risk factor for car-
diovascular disease. Antihypertensive treatment can effectively lower cardiovascular
disease risk by reducing elevated pressure, but over-aggressive treatment can increase
risk. Current guidelines for administering antihypertensive treatment are based on
randomized control trials which are limited by resource constraints in what they
can examine. We develop data-driven mathematical models to optimize treatment
decisions, monitor blood pressure from mobile health technologies, and maximize
population health.
In chapter I, we introduce background knowledge on the clinical characteristics
of cardiovascular disease and blood pressure. This introduction frames the context
of the thesis and justifies assumptions we make about the disease progression and
treatment. We proceed to offer a summary of the remaining chapters, detailling the
objectives, methodologies, and contributions of each chapter.
In chapter II, we show that history of a patient’s blood pressure is an important
predictor of future cardiovascular risk. Standard risk prediction models consider
only a patient’s current blood pressure and ignore history. Using Cox model survival
analysis and the Framingham Heart Study data set, we demonstrate antecedent blood
pressure is a more significant predictor of cardiovascular disease than current pressure.
The model’s predictive ability is significantly improved by the addition of antecedent
pressure, demonstrating the predictive value of historical measurements. We confirm
these findings in other data sets and with different baselines, lengths of history, and
xv
follow-up intervals. The results of this chapter motivate the following chapters by
emphasizing the importance of a time integrated measure of blood pressure as a risk
for cardiovascular disease.
In chapter III, we develop a population level optimal antihypertensive treatment
policy. We model blood pressure as a continuous time, continuous state stochastic
process, specifically a geometric Brownian motion mixture model, which we demon-
strate is a good statistical fit. Using published parameters of cardiovascular disease
risk as a function of blood pressure, we create a closed form analytical expression
for the expectation and variance of hazard a patient experiences over the following T
years as a function of their current blood pressure and drift and covariance of change
over time. Using meta-analyses of randomized control trials, we estimate the effects of
different dosages of antihypertensive treatment and optimize over treatment decisions.
We create a threshold based population level optimal treatment policy for initiation
and intensification of antihypertensive treatment, and show significant improvement
over current guidelines in a large scale simulation model.
In chapter IV, we develop two changepoint detection-based algorithms for screen-
ing blood pressure from wearables and other mobile health technologies. Such devices
are becoming more ubiquitous and can gather many more measurements than tra-
ditional clinical measurements. The first algorithm uses knowledge of the disease
progression to maintain a Bayesian belief of the true state. This method is highly
accurate, but may be difficult to implement in practice due to the parameter estima-
tion and necessity of simulation to calibrate the algorithm. We subsequently develop
a Naive changepoint detection algorithm that is simple and generalizable to other






Cardiovascular disease (CVD) is the leading cause of death worldwide and within the
United States [1, 2]. The American Heart Association reports that approximately
800,000 deaths in the United States are attributable to CVD every year and financial
burden exceeds 300 billion dollars in healthcare and lost productivity [3]. Many of the
causes of CVD are controllable through medication or lifestyle change, so improving
our knowledge of risk factors over time and how they may affect CVD risk is worthy
of investigation.
CVD is a group of disorders of the heart and blood vessels including coronary
heart disease, cerebrovascular disease, peripheral arterial disease, and others [4]. The
acute events most associated with CVD are heart attack, which occurs when the
blood flow to the heart is blocked by a blood clot, and ischemic stroke, which is when
a blood vessel to the brain is blocked [5]. Other associated events are heart failure,
which is when the heart isn’t pumping blood as strong as it should, and arrhythmia,
abnormal rhythms of the heart [5].
There are many known risk factors for CVD. Age, sex, diabetes, and certain ge-
netic markers are uncontrollable risk factors. Controllable factors include cholesterol,
smoking, body mass index, and elevated blood pressure (BP). Of particular interest,
and the central focus of this thesis, is blood pressure. Blood pressure comprises two
measurements, systolic (SBP) and diastolic (DBP), both measured in millimeters of
mercury (mm Hg); elevated BP is referred to as hypertension. BP is typically reported
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as systolic and diastolic with a ‘/’ character between, and for example BP 120/80 is
pronounced ‘120 over 80’. BP is a ubitiquous measure, and is taken virtually anytime
meeting a physician [6, 7]. Typically it is recorded with a mercury sphygmometer by
a trained health professional, but automatic measurement is an option that reduces
human effort but is less accurate [8, 9, 10].
Behavior interventions such as healthier diet, salt reduction, smoking cessation,
and increased physical activity have been demonstrated as effective for reducing BP,
improving health, and reducing the risk of CVD [11, 12]. Since these behavioral mod-
ifications promote overall health and are costless, they are universally recommended
by physicians [13]. For patients whose BP remains elevated, they can begin an oral
regimen of drugs designed to reduce BP, called antihypertensive drugs, detailled in §
1.1.4.
1.1.2 Framingham Heart Study
The Framingham Heart Study was the first study of its kind to investigate cardio-
vascular risk factors in a longitudinal cohort [14]. It was instrumental in establishing
that blood pressure and other risk factors preceded the development of cardiovascu-
lar disease, and were not unavoidable side effects, as previously believed [15]. It was
one of the key studies to identify the health risks of smoking [16]. To this day the
Framingham Heart Study remains the largest, longest tracked longitudinal cohort for
cardiovascular disease and has funding from the National Heart, Lung, and Blood
Institute (NHLBI). The Framingham Risk Score which predicts the risk of cardiovas-
cular disease is still used as the gold standard today [17, 18] and recommended by
the NHLBI. [19].
The Framingham Heart Study contains two major sub-studies, the Original Cohort
(FHS) and the Offspring Cohort (FOS). Both studies contain major advantages and
disadvantages, which we detail presently. We will make extensive use of both studies
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throughout this thesis. Both studies are still to this day tracking patients.
The Original Cohort consisted of 5,209 men and women who were free of CVD
between the ages of 30 and 62 recruited beginning in 1948 in Framingham Mas-
sachusetts [20]. Beginning at their initial examination, patients attended a follow-up
exam every 2 years. A variety of clinical and behavioral characteristics were recorded
at each examination, including age, blood pressure, diabetes status, smoking status,
and what medications each patient was taking. Exam 32 of the Original Cohort, the
most recent as of this publication, concluded in April 2014.
The Offspring Cohort began in 1971 with 5,124 men and women, consisting of the
offspring of the Original Cohort and their spouses [21]. Eight years passed between the
first and second examination, and four years between every subsequent examination.
Measurements at each exam were similar to those taken in the Original Cohort,
with added information regarding genetic markers and the inclusion of cholesterol
measurements. Exam 9 of the Offspring Cohort, the most recent as of this publication,
concluded in April 2014.
From a modeling perspective, the advantages of the Original Cohort are more
frequent observations, a longer history, and a very small percentage of patients tak-
ing antihypertensive medication. Antihypertensive medication was less widespread
because they had not yet been demonstrated as effective in reducing risk of cardio-
vascular disease. Patients taking antihypertensive medication complicate modeling,
since their pressures will be lowered to various extents depending on how long they
have been taking the medications. The disadvantage of the Original Cohort is lack
of cholesterol measurements. Cholesterol measurements are frequently not recorded
at examinations, and when they are, low-density lipoproteins (LDL), or “bad choles-
terol” is merged together with high-density lipoproteins (HDL), or “good cholesterol”.
This blend of good and bad cholesterol makes any measurements useless in predictive
ability. Another disadvantage is the demographics and behavioral characteristics are
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not representative of today because of the age of the data. We will make use of the
data from this study in chapters III and IV of the thesis for modeling change in blood
pressure over time because of the more abundant measurements, less time between
measurements, and lack of complications from antihypertensive medication. While
the distribution of blood pressure values in the population may have changed in recent
history, it is reasonable to believe that the physiology of blood pressure progression
has not changed appreciably since these studies, so the older data is not problematic.
The advantages of the Offspring Cohort are more measurements per exam and a
more modern data closer indicative of the demographics and behavioral characteristics
of today. Scientific advances permit the collection of LDL and HDL cholesterol values
separately at each exam, adding them as useful risk factors for prediction. The
downsides are fewer examinations due to the more recent start date, less length of
followup, and longer intervals between observations. We will make use of the data
from this study in chapter II for developing risk prediction models of cardiovascular
disease. All modern risk equations are built on the Offspring Cohort owing to a more
modern data set with more predictor variables. The characteristics of each study and
how we make use of them in this thesis are presented in table 1.1.
1.1.3 J-Curve Effect
In the 1960’s, the first studies from the Framingham Heart Study identified elevated
BP as a risk factor for cardiovascular disease and all-cause mortality [22]. In 1979,
Stewart reported increased risk for patients with SBP < 130 or DBP < 85− 90 [23].
This was referred to as the J-Curve effect, so named because risk is lowest at an
intermediate pressure, with increasing risk on either side of optimal [24]. See Figure
1.1 for a visualization of this phenomenon. While a few earlier trials have found
no support [25, 26], there exists strong evidence for the existence of this effect [27].
Several recent clinical trials have validated the J-Curve effect in the general population
4






















Used in this thesis Chapters III and IV -
parametrizing BP progres-
sion model
Chapter II - risk prediction
models
[28, 29] or in specific subpopulations [30, 31, 32]. Other studies have demonstrated
no value in initiating antihypertensive treatment in patients with intermediate risk
and moderate-low pressures [33], and an increase in cardiovascular risk in patients
with low pressure placed on antihypertensive treatment [34].
The existence of the J-curve effect has important clinical implications, imposing
fundamental tradeoffs in BP management. Aggressive treatment may lower BP below
optimal, thereby increasing risk. The tradeoffs are further complicated when consid-
ering systolic and diastolic BP jointly. For example, consider a patient with high
SBP and moderate-low DBP (referred to as isolated systolic hypertension). Placing
this patient on treatment will lower their SBP and subsequently lower risk, but con-
currently lower DBP and, due to the J-curve effect, increase risk. The decision of
whether to initiate treatment must weigh the benefits of SBP reduction against the
penalty of DBP reduction.
5




























Diastolic BP Systolic BP
J Curve Relationship Between BP and Mortality/ESRD
Figure 1.1: J-curve effect of diastolic and systolic blood pressure on mortality and
end-stage liver disease. Figure adapted from [35].
1.1.4 Antihypertensive treatment
Antihypertensive drugs have been instrumental in improving public health [36, 37].
The drugs are widely effective, cheap, and with minimal side effects. [38] estimate
that use of antihypertensives prevented 86,000 premature deaths from cardiovascular
disease in 2001. They are extremely cheap, estimated at $212 for one year of generic
BP treatment [39, 40].
There are 5 primary classes of hypertension drugs: thiazides, β blockers, an-
giotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists,
and calcium channel blockers [41]. In a review of 354 randomised trials, Law et. al.
2003 [42] found that all five categories of drug produced similar reductions in blood
pressure. They found that within a given dose, few statistically significant differ-
ences existed, and no category of drug was overall more effective than another. We
will therefore ignore categories of drugs, and consider only dosage and pre-treatment
pressure.
In a meta-analysis of randomized control trials, Law et. al. [43] explored the
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cause of CVD risk reduction from antihypertensive treatment. They report there
was a 31.5% reduction in CVD events for a blood pressure reduction of 10 mm Hg
systolic or 5 mm Hg diastolic, similar to the 30.5% expected reduction from the
blood pressure reduction owing to antihypertensive treatment, indicating the benefit
of antihypertensive treatment is explained by the blood pressure reduction itself. That
is, the reduction in CVD from antihypertensive treatment is explained entirely by the
blood pressure lowering, with no additional CVD reduction beyond that predicted
by the blood pressure reduction. We are therefore justified in assuming all the value
of antihypertensive treatment comes from the blood pressure reduction. They also
find that the almost full potential effect of blood pressure reduction from treatment
is achieved within a year, so we will model treatment accordingly.
It is generally accepted in clinical practice that the adverse effects of hypertensive
treatment are small or negligible [44]. [43] verify this assumption by performing a
meta-analysis of randomized control trials. The most common symptoms attributable
to each class of drug are: thiazides - dizziness, impotence, nausea, muscle cramps; β
blockers - cold extremities, fatigue, nausea; ACE inhibitors - cough; calcium channel
blockers - flushing, ankle oedema, dizziness. [42] find that at standard dose, 9.9%
more patients taking thiazides report symptoms (compared to placebo), 8.3% of those
taking calcium channel blockers, 7.5% of those taking β blockers, and 3.9% of those
taking ACE inhibtors. Considering higher dosages, they find adverse effects are less
than additive in dosage. They find the prevalence of symptoms sufficiently severe to
stop treatment was under 1% across all drug categories. These adverse effects are
minor enough that we will examine blood pressure treatment decisions solely based
on reduction in cardiovascular events.
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1.1.5 Blood Pressure Monitoring
Traditionally, BP was measured at annual clinical examinations or other office visits.
These measurements are quite accurate, being taken by trained health professionals
following guidelines for proper BP measurement [45]. Individuals suspected of having
hypertension were given home or ambulatory BP monitors, recorded frequently for a
length of time (typically one week to one month), and the average BP was calculated.
Patients with average BP above a threshold value, typically systolic 140 mm Hg or
diastolic 90 mm Hg, initiated antihypertensive treatment [36].
Wearables and other devices associated with the Internet of Things, collectively
known as mobile health (mHealth), have the potential to revolutionize the manage-
ment of chronic disease. Specifically, mHealth provides new opportunities for screen-
ing and monitoring BP in non-clinical settings [46]. As of August 2017, the Consumer
Technology Association forecasted the sale of wearables would reach 48 million units
and earn $5.5 billion in revenue in 2017 [47]. The largest categories in these sales
are fitness trackers and smart watches, which measure and record vital measurements
(VMs) such as pulse, heart rate variability, blood oxygenation, and blood sugar. In
addition to these existing technologies, innovative new ones have the potential to
make health measurements even more ubiquitous, such as the Ford Motor Company
exploring the integration of blood pressure sensors in their vehicles [48] and the Mi-
crosoft Kinect video game console measuring heart rate with infrared cameras [49].
In January 2018, Omron Healthcare debuted a wearable BP monitor that will enter
the marketplace fall 2018 [50]. These devices offer access to unprecedented amounts
of individual, patient-level data that are recorded at short intervals. It is anticipated
that by 2020, even more wearables may be capable of blood pressure monitoring [51].
Many of these technologies integrate with smartphones to provide data tracking and
visualization. However, the data analytics potential of these measurements remains
largely unexplored [52]. Statistical and mathematical models can analyze the data
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from these technologies and improve patient level health outcomes.
1.2 Chapter II: Antecedent Blood Pressure as Predictor of Cardiovascu-
lar Disease
Cardiovascular disease risk prediction equations input the risk factors of an individ-
ual and output that individual’s likelihood of developing CVD in some future time
window. Risk prediction models built on the Framingham Offspring data set are
common in clinical practice, and regarded as the gold standard. This study aims to
improve the prediction model by incorporating a novel risk factor, antecedent blood
pressure. Current risk prediction models are based on only current pressure, and do
not consider the blood pressure history of patients.
1.2.1 Objectives
Our objectives in this study are to improve the predictive ability of CVD risk equations
and demonstrate history of blood pressure is a significant predictor of CVD. We wish
to demonstrate history of a patient’s blood pressure matters, and risk is not solely
determined by current pressure. This motivates further chapters by necessitating a
time integrated measure of risk.
1.2.2 Methodology
We develop risk equations using Cox proportional hazard survival models built on
the Framingham Offspring data, considering exam 3 as the baseline. We consider
both simple age and sex adjusted models, and full models with a complement of
risk factors. To each we examine model improvement when adding simple average of
patients’ BP at exams 1 and 2. To compare the predictive power of these models and
explore if the differences are significant, we utilize C-statistic (concordance) tests, net
reclassification (NRI), and integrated discrimination improvement (IDI).
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1.2.3 Contribution
We find that antecedent systolic blood pressure is a statistically significant predictor
of CVD. When antecedent pressure is added to a traditional risk factor model, current
BP becomes not statistically significant. A reasonable conclusion is that long-term
information related to blood pressure continues to be relevant and higher BP levels
in the past may exert long term effects on CVD risk. This finding motivates the
following chapter by demonstrating the importance of a time integrated risk of CVD.
1.3 Chapter III: Analytics Approach to Blood Pressure Control
The current widely adopted guidelines for initiating antihypertensive treatment [36]
suggest initiating treatment in patients < 60 years old with SBP≥ 140mm Hg or DBP
≥ 90 mm Hg. However, these guidelines are based on randomized control trials which
are limited in the thresholds they can examine. Recent evidence from a significant
clinical trial [53] suggest the thresholds should be lowered, but there is no consensus
and no data exist to suggest what the optimal thesholds should be. This study aims
to develop a longitudinal model of blood pressure progression in the population and
use that model to determine optimal treatment initiation thresholds.
1.3.1 Objectives
The first objective of this study is to find optimal antihypertensive treatment initiation
and dosage thresholds, which can both recommend future RCT design and serve as
a decision support tool. This can improve public health by defining data-driven
guidelines for antihypertensive treatment and exploring potential improvements in
hypertension management by recommending promising options for exploration in
RCTs. A secondary objective of this study is to develop a continuous time, continuous
space model of systolic and diastolic blood pressure progression. Existing models of
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blood pressure are Markovian and typically have a small state space corresponding to
definitions of hypertension. Such an approach may also be useful for modeling other
continuous health measurements such as cholesterol, blood glucose, and body mass
index.
1.3.2 Methodology
We model systolic and diastolic blood pressure as a continuous time stochastic process,
specifically a geometric Brownian motion mixture model. We parametrize the BP
progression model using Framingham Original data. We fit a model of CVD risk
of blood pressure, parametrized by a large population level study. We model the
blood pressure lowering effects of antihypertensive treatments and parametrize from
a large meta-analysis of clinical trials. By integrating the risk of blood pressure over
time using the fitted progression model, we derive an analytical expression of the
expectation and variance of hazard experienced by a patient over the following T
years as a function of current pressure. We solve a mean-variance optimization model
to find the optimal treatment initiation and dosage intensification thresholds. This
model allows us to capture different attitudes towards risk, for example risk-neutral or
risk-averse. We show the distribution of incurred hazard ratio does not follow a simple
form, yet we construct approximate confidence intervals using radial basis functions.
We conduct a simulation study to compare our policy to existing guidelines.
1.3.3 Contribution
This work makes contributions in both the methodological and clinical domains. From
the methodological perspective, we provide a novel mixture-based continuous time,
continuous space model of disease progression. The model is robust to distributional
forms owing to the flexibility of Gaussian mixtures. Such a model can be used for
other health care measurements such as cholesterol, blood glucose in diabetics, and
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body mass index. Our analytical solution of the expected value and variance of the
hazard ratio is a novel theoretical contribution, as most models in the health domain
derive solutions from iterative numerical approaches. From a clinical perspective, our
findings have several policy implications which may guide RCT designs and merit fur-
ther testing in future clinical trials: 1) while the current guidelines consider systolic
and diastolic pressure treatment thresholds independently, thresholds that jointly de-
pend on both measurements may substantially improve health outcomes, 2) similar to
treatment initiation decisions, there exist optimal treatment intensification threshold
levels, that are likely to improve clinical outcomes, 3) while current guidelines suggest
treating both cases of isolated hypertension, there may be tradeoffs associated with
treating mild isolated diastolic hypertension. Our simulation model demonstrates
significant improvement of our policy over current guidelines, saving an estimated
additional 15 thousand premature deaths from hypertension annually. An advantage
of our approach as a decision support tool is the construction of confidence intervals
on hazard ratio experienced by a patient taking various treatments. This allows users
to weigh the relative benefit of treatments with exogeneous factors such as patient
preference, cost, and potential side effects.
1.4 Chapter IV: Personalized Blood Pressure Management
Wearables and other mobile health technologies have the potential to revolutionize
the management of chronic disease. Fitness trackers and smart watches can measure
and record vital measurements such as pulse, heart rate variability, blood oxygena-
tion, blood sugar, and blood pressure. These devices offer access to unprecedented
amounts of individual, patient-level data that are recorded frequently. Statistical
and mathematical models can analyze the data from these technologies and design
effective disease monitoring tools.
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1.4.1 Objectives
The objective of this chapter is to design statistical and mathematical methods that
use measurements from wearables or other technologies to make screening decisions
for chronic diseases. We aim to develop a changepoint detection algorithm that signals
the user when the likelihood the vital measurement has exceeded some threshold value
is high. Such a signal may suggest the user follow up with a clinician for diagnosis and
treatment options (for example, in the case of blood pressure or cholesterol) or take
immediate action (for example, an elevated heart rate or low blood glucose level).
The proposed algorithms are able to incorporate sporadically timed observations to
reflect the usage of mobile health technologies.
1.4.2 Methodology
We first design a Bayesian belief-based changepoint method that uses knowledge of
the disease progression and measurement error in the mobile technology. Our analyses
find this method performs quite well, but remark the difficulty in implementation of
such a procedure. Specifically, the exact disease progression distribution is required,
and simulations must be conducted to estimate the desired sensitivity and specificity.
Motivated by the implementation difficulties of this procedure, we next develop a
Naive changepoint procedure that makes few assumptions and is applicable to a
wide variety of health measurements. Finally, we demonstrate the effectiveness of
our algorithms on simulated blood pressure data and show the improvement in our
algorithms over benchmark policies.
1.4.3 Contribution
Tthis work provides two algorithms that use frequent, highly noisy observations of
blood pressure or other vital measurements to decide if the measurement has risen
above a specified threshold. If the disease progression is known and calculations can
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be performed to calibrate algorithm performance, the Bayesian changepoint approach
has good performance. On the other hand, this may face challenges in practice,
and if the disease progression is unknown or simulations are not possible, the Naive
changepoint provides a simple way of analyzing the measurements at the price of
slightly worsened performance. Methodologically, our work develops changepoint




ANTECEDENT BLOOD PRESSURE AS PREDICTOR OF
CARDIOVASCULAR DISEASE
2.1 Introduction
As discussed in chapter I, prior research has identified many risk factors for CVD,
including age, sex, cholesterol, smoking, diabetes, and elevated levels of BP [54].
Many of the causes of CVD are controllable through medication or lifestyle change,
so improving our knowledge of risk factors over time and how they may affect CVD
risk is worthy of investigation. Most risk estimate models use a patient’s current blood
pressure and ignore history of BP [55]. Clinical studies have indicated that a patient’s
BP history may be an important factor [56, 57, 58]. Many patients exhibit high BP
variability over time [59, 60], and the most recent point estimate may not capture
this information. Furthermore, long-term exposure to elevated BP levels may have
important effects on CVD risk. Antecedent BP includes some of this information,
and may have meaningful effects on a patient’s CVD risk status.
In this chapter we examine the potential effects of incorporating antecedent BP
into modern CVD risk prediction models. Previous studies examining antecedent BP
as a risk factor [57] have examined an older cohort in the Framingham Original study.
Anti-hypertensive treatment has improved since the data examined in that study, and
more detailed cholesterol information is available. Other CVD risk studies examining
changes in BP over time only classify individuals by stage of hypertension [58]. Studies
that incorporate antecedent pressures report current, recent, and remote measures,
without considering trends within an individual [61]. In this chapter we consider the
improvement in risk prediction from adding additional BP measurements over time.
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We further consider whether stage of antecedent hypertension is sufficient to improve
risk prediction, or if exact antecedent pressures are necessary. This study motivates
further questions regarding how much BP history is relevant to CVD prediction, and
how best to weigh past measurements.
2.2 Methods
2.2.1 Population Sample
As discussed in § 1.1.2, the Framingham Heart Study is a longitudinal observational
study that began in 1948. The Offspring Cohort began in 1971 with approximately
5000 participants and was used to undertake the data analyses. Exam 1 collected
data from 1971-1975, exam 2 from 1979-1983, and exam 3 from 1983-1987. This
work was approved by the Emory Institutional Review Board and public-use data
were accessed through the National Institutes of Health.
2.2.2 Study Inclusion
We included data from Offspring Study participants who attended Exam 3 if they
met the following criteria: (1) individuals must not have had any cardiovascular event
(myocardial infarction, angina pectoris, stroke, intermittent claudication, or cardiac
failure) at the time of exam 3 or prior to that date, (2) participants had a systolic
blood pressure measurement from exam 1 and potentially from exam 2, (3) all other
CVD predictors were recorded at exam 3, and (4) study subjects must have either a
recorded death time or last known time alive. Out of 3765 participants who attended
exam 3, a total of 3344 met these selection criteria (1604 men, 1740 women). Persons
with missing data values were omitted, and no interpolation was performed. There
was an 8 year interval between exams 1 and 2, and 4 years between exams 2 and 3.
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2.2.3 Clinical Measurements
There were 3344 participants who satisfied the selection inclusion criteria. Blood
pressure was measured at the FHS with the subject sitting for at least five minutes
using an appropriate cuff size. The BP measurements for this project were per-
formed using a mercury column sphygmomanometer with quality control evaluations
of the staff who made the measurements. BP was measured twice by a clinician for
each participant at each exam, and the average of these determinations was used as
the BP in the analyses. Antecedent systolic BP was defined as the simple average
of the BP measurements at exams 1 and 2. For the 416 participants missing BP
measurements at exam 2, the exam 1 measurement was used as the antecedent. A
study subject was considered on treatment for hypertension if the participant either
reported currently taking one of a number of drugs designed to lower blood pres-
sure, or if the offspring exam records indicated that the person was being treated
for hypertension. The specific drugs included at exam 1: diuretics for fluid retention
or BP and hypotensive medications; exam 2: propanolol, hypotensive medications,
aldomet, spironolactone, and diuretics for hypertension or other; exam 3: calcium
channel blockers, beta blockers, peripheral vasodilators, diuretics, potassium sparing
diuretics, reserpine derivatives, methyldopa, clonidine, wytensin, ganglionic blockers,
renin angiotensin blockers, and other anti-hypertensive drugs. Cigarette smoking was
assessed by questionnaire based on regular smoking over the past year.
Cholesterol was determined using enzymatic methods and HDL cholesterol was
measured after precipitation of plasma with dextran sulfate. Diabetes was considered
present if the subject took glucose lowering medication or if fasting glucose was greater
than 126 mg/dl.
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2.2.4 Follow Up for Cardiovascular Disease Outcomes
Participants were followed until they first experienced a CVD event or until 20 years
after the exam 3. We defined a CVD event as death by CVD, myocardial infarction,
coronary insufficiency, cerebrovascular disease, intermittent claudication, or conges-
tive heart failure. Cardiovascular events were adjudicated by a panel of 3 Framingham
clinicians using endpoint criteria that have in place since the start of the study and
have been published in official documentation [62]. Participants not experiencing an
event were censored at the time of their death or at the time they were last known
to be alive.
2.2.5 Statistical Methods
Survival analysis is concerned with analyzing the duration of time until events occur,
such as a CVD event. There are two components to a survival model, the baseline
hazard function λ0(t) and a function h(t). The underlying baseline hazard function
λ0(t) describes the baseline hazard for an average individual with baseline values of
the predictor variables. The function h(t) describes how the hazard varies with the
predictor variables. The Cox proportional hazards model assumes these functions are
multiplicative in describing the hazard λ(t) for an individual [63]. The hazard for a
particular individual λ(t) is thus described as
λ(t) = h(t)λ0(t) = λ0(t) exp(β1X1 + · · · βnXn),
where βi are fitted coefficients and Xi are the predictor variables. Under this model,
the hazard ratio (HR) of a predictor Xv is given by exp(βv), meaning a one unit
increase in Xv corresponds to a multiplicative increase in hazard of exp(βv).
Cox proportional hazards models were used to evaluate the strength of various
variables in predicting CVD risk. We first created simple age- and sex- adjusted risk
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models using current systolic BP, antecedent systolic BP, and both BP measures. We
next created multivariable Cox models. The conventional model used age, cholesterol,
HDL cholesterol, and systolic BP at exam 3 as continuous variables. Sex, smoking,
diabetes, and BP treatment were used as categorical variables. The antecedent model
included all of these variables, except antecedent BP was used in place of systolic BP.
Finally, a full model contained all of these variables and both BP measurements. We
also created models examining history of hypertension (exam 1 or 2 BP measurement
< 140 or on BP treatment) as a predictor instead of the exact antecedent BP.
To compare the predictive power of these models and explore if the differences
were significant, we utilized C-statistic (concordance) tests [64], net reclassification
(NRI) [65], and integrated discrimination improvement (IDI)[65]. The IDI test is a
measure of the new model’s improvement in average sensitivity without reduction in
average specificity, and the NRI test examines the upward and downward movement
of predicted risk in those with and without events. We performed two versions of the
NRI test, continuous and categorical. The former tests the incremental differences
in predicted probabilities, and the categorical test considers movement between pre-
defined ranges of risk. We used CVD risk category boundaries derived from tertiles
of risk. The net estimate for the percentage reclassified is calculated separately for
those experiencing events and not. For those with events, it is defined as the number
of individuals reclassified upwards minus the number of individuals reclassified down-
wards, divided by the total number of individuals with events, and for those without
events it is the number reclassified downwards minus the number reclassified upwards
divided by the number of individuals without events.
2.2.6 Secondary Analyses
To assess the robustness of our findings, we considered secondary analyses. The mod-
els described above were run with diastolic BP instead of systolic. Further models
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Table 2.1: Summary Statistics, Framingham Offspring Exam 3
Predictor Overall Men WomenCase NonCase Case NonCase
# Participants 3344 414 1190 229 1511
# CVD Events 643
Age 47.8 ± 10.0 52.5 ± 9.3 46.2 ± 9.9 54.1 ± 9.0 46.7 ± 9.6
Smoking (yes/no) 28.9% 31.1% 27.2% 36.7% 28.2%
Diabetes (yes/no) 3.2% 10.4% 1.8% 9.2% 1.5%
Cholesterol (mg/dL) 210.9 ± 40.9 221.0 ± 38.1 207.8 ± 38.2 236.2 ± 48.9 206.6 ± 40.8
HDL Cholesterol (mg/dL) 51.5 ± 14.8 43.4 ± 11.9 46.1 ± 12.1 53.1 ± 15.3 57.8 ± 14.6
BP Treatment (yes/no) 15.4% 27.8% 11.2% 34.5% 12.3%
Current Systolic BP (mm Hg) 123.4 ± 16.6 131.0 ± 15.9 124.1 ± 14.6 131.6 ± 18.1 119.5 ± 16.7
Antecedent Systolic BP (mm Hg) 121.0 ± 14.7 130.1 ± 14.6 123.1 ± 12.6 126.3 ± 17.6 116.1 ± 14.0
Frequencies and means ± standard deviation are shown in the table.
were run with mean arterial pressure [66] instead of systolic BP. To examine if ad-
ditional antecedent BP measurements can provide additional value, we considered a
series of models using exam 5 as baseline and 2,3,or 4 previous exams of antecedent
measurements. Finally, we considered models with follow up only for hard CVD
events (death by CVD, MI, or stroke.)
2.3 Results
2.3.1 Study Sample Characteristics
A summary of the population sample characteristics is shown in Table 2.1 for the
3344 participants (1604 men, 1740 women) in the study. Men had higher baseline
prevalence of diabetes than women (3.9% versus 2.5%), higher current systolic blood
pressure (125.8 mm Hg versus 121.1 mm Hg), higher antecedent blood pressure (124.8
mm Hg versus 117.5 mm Hg), and lower HDL cholesterol (45.3 mg/dL versus 57.2
mg/dL). The number of participants on antihypertensive medications at exams 1,2,
and 3 were 112, 317, and 515, respectively. The correlation between exam 3 BP and
antecedent BP is 0.696, and the variance inflation factors for current and antecedent
BP were < 2, indicating no presence of multicollinearity. During 20 years of follow
up, there were 643 participants (414 men, 229 women) who experienced a CVD event
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Table 2.2: Age and Sex Adjusted Cox Models
Units Current BP Model Antecedent BP Model Current + Antecedent BP Model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 1 year 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) (1.05-1.07) 1.06 (1.05-1.07) <0.001
Male 2.23 (1.89-2.62) <0.001 2.08 (1.77-2.45) <0.001 2.09 (1.77-2.46) <0.001
Current Systolic BP 10 mm Hg 1.18 (1.12-1.14) <0.001 1.07 (1.00-1.13) 0.02
Antecedent Systolic BP 10 mm Hg 1.27 (1.20-1.33) <0.001 1.22 (1.15-1.30) <0.001
C Statistic 0.735 (0.716,0.753) 0.740 (0.722,0.759) 0.742 (0.724,0.760)
AIC 9736 9704 9701
Chi-Square 452 496 499
(a) Hazard ratio and confidence intervals
Performance Current + Antecedent Current + Antecedent
vs. Current vs. Antecedent
C Statistic Test p=0.007 p=0.06
IDI 0.005 (0.001,0.010) 0.001 (0.000,0.003)
Relative IDI 0.050 (0.008,0.092) 0.009 (-0.004,0.024)
NRI continuous 0.149 (0.062,0.238) 0.146 (0.061,0.236)
NRI categories 0.060 (0.0024,0.097) 0.008 (-0.009,0.025)
(b) Model comparison
(19%).
2.3.2 Age and Sex Adjusted Simple Cox Models
Table 2.2 presents the results of the age- and sex- adjusted simple Cox models. Both in
the antecedent and the full model, antecedent BP is statistically significant (p< .001).
Current BP is a statistically significant predictor in both the conventional model and
the full model. The C-index of the full model (0.742, CI 95%: 0.724 - 0.760 ) is
significantly higher (p=0.007) than that of the conventional model, which implies
that considering antecedent BP in addition to current BP significantly improved the
reclassification ability. Comparing the full model to the antecedent model, the C-
test, NRI, and IDI tests all indicate no significant improvement, suggesting that
conventional BP does not improve discrimination by reclassification when antecedent
BP is used.
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Table 2.3: Multivariate Cox Models
Units Current BP Model Antecedent BP Model Current + Antecedent BP Model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 1 year 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001
Male Yes/No 2.07 (1.74-2.47) <0.001 1.99 (1.66-2.37) <0.001 1.99 (1.66-2.37) <0.001
Smoking Yes/No 1.64 (1.38-1.94) <0.001 1.71 (1.44-2.03) <0.001 1.71 (1.44-2.03) <0.001
Diabetes Yes/No 2.48 (1.89-3.25) <0.001 2.31 (1.75-3.04) <0.001 2.30 (1.75-3.02) <0.001
Total Cholesterol 10 mg/dL 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001
HDL Cholesterol 10 mg/dL 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001
Current BP Treatment Yes/No 1.66 (1.38-2.00) <0.001 1.42 (1.16-1.74) <0.001 1.43 (1.17-1.74) <0.001
Current Sys BP 10 mm Hg 1.09 (1.04-1.15) <0.001 1.01 (0.95-1.08) 0.73
Ant Sys Bp 10 mm Hg 1.19 (1.12-1.26) <0.001 1.18 (1.09-1.27) <0.001
C Statistic 0.771 (0.754,0.788) 0.774 (0.756,0.791) 0.774 (0.757,0.791)
AIC Statistic 9582 9567 9568
Chi-square value 693 712 712
(a) Hazard ratio and confidence intervals
Performance Current + Antecedent Current + Antecedent
vs. Current vs. Antecedent
C Statistic Test p=0.04 p=0.29
IDI 0.002 (-0.003,0.007) 0.000 (0.000,0.001)
Relative IDI 0.008 (-0.015,0.033) 0.002 (-0.003,0.007)
NRI continuous 0.153 (0.034,0.277) 0.03 (-0.087,0.149)
NRI categories 0.0289 (0.004,0.054) -0.001 (-0.010,0.009)
(b) Model comparison
2.3.3 Multivariate Models
Table 2.3 presents the results of the multivariable Cox models. Antecedent BP is a
significant predictor in both the antecedent and full models. Current BP is a statisti-
cally significant predictor in the conventional model but not in the full model. That
is, when considering antecedent BP, antihypertensive treatment, and all other covari-
ates, current BP is not significant. The C-index of the full model (0.774, CI 95%:
0.754 - 0.788) is significantly higher (p=0.04) than that of the conventional model.
Both the continuous and categorical NRI tests indicate a significant improvement in
the full model over the conventional model, but the IDI test does not indicate a sig-
nificant improvement. Comparing the full model to the antecedent model, the C-test,
NRI, and IDI tests all indicate no significant improvement. The effects of reclassifica-
tion were assessed with the categorical NRI test using categories found from tertiles
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Table 2.4: Antecedent Hypertension Models
Units Current BP Model Current + Antecedent BP Model
HR (95% CI) p value HR (95% CI) p value
Age 1 year 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001
Male Yes/No 2.07 (1.74-2.47) <0.001 2.07 (1.74-2.47) <0.001
Smoking Yes/No 1.64 (1.38-1.94) <0.001 1.66 (1.40-1.96) <0.001
Diabetes Yes/No 2.48 (1.89-3.25) <0.001 2.45 (1.87-3.22) <0.001
Total Cholesterol 10 mg/dL 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001
HDL Cholesterol 10 mg/dL 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001
Current BP Treatment Yes/No 1.66 (1.38-2.00) <0.001 1.61 (1.32-1.96) <0.001
Current Sys BP 10 mm Hg 1.09 (1.04-1.15) <0.001 1.08 (1.03-1.14) 0.004
Antecedent Hypertension Yes/No 1.12 (0.90-1.40) 0.317
C Statistic 0.771 (0.754,0.788) 0.771 (0.754,0.789)
AIC Statistic 9582 9583
Chi-square value 693 699
(a) Hazard ratio and confidence intervals
Performance Current + Antecedent
vs. Current
C Statistic Test p=0.51
IDI 0.000 (-0.001,0.001)
Relative IDI 0.000 (-0.001,0.001)
NRI continuous -0.096 (-0.185,0.000)
NRI categories 0.007 (-0.001,0.018)
(b) Model comparison
of risk to be 0.0457 and 0.1179. The NRI test indicates significant reclassification
within these categories. A total of 18 subjects who developed CVD were reclassified
upward, and 6 subjects who developed an event were reclassified downwards, for a net
estimate of 2.5%. Similar calculations for individuals who did not develop an event
revealed 101 subjects reclassified downwards, and 89 subjects reclassified upwards, for
a net estimate of 0.4%. The IDI test gave a result of 0.0012 and was not statistical
significant. Reclassification information according to the different categories of risk
is available in the appendix.
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2.3.4 Hypertensive History
Table 2.4 displays the multivariable results using an antecedent hypertension indicator
variable. Hypertension, expressed as a yes/no variable in the prediction model, was
not statistically significant (p=0.32). The hazard ratios for exam 3 systolic BP and




Table 2.5 gives the results of running the survival models using diastolic pressure
instead of systolic. The results are similar to those of systolic: the full plus antecedent
model is a statistically significant improvement over the current model, and there is
no improvement in the full plus antecedent model over the antecedent model. The
hazard ratio of 10 mm Hg current diastolic pressure is 1.12, while that of antecedent
pressure in the antecedent model is 1.33. When both terms are added to the model,
current diastolic pressure is insignificant, and antecedent pressure has a hazard ratio
of 1.36. We also notice the diminishing effect of BP treatment, as the case with
systolic models: in the current model, the hazard ratio of BP treatment is 1.69, while
that in the antecedent model is only 1.41.
Mean Arterial Pulse
Table 2.6 gives the results of running the survival models using mean arterial pressure
instead of either blood pressure measurement. The results are consistent with the
findings from the antecedent blood pressure models. These results are not surprising,
since MAP is a convex combination of systolic and diastolic pressures, we would
expect the hazard to be consistent with both pressure measurements.
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Table 2.5: Antecedent Diastolic Pressure Models
Units Current BP Model Antecedent BP Model Current + Antecedent BP Model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 1 year 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001
Male Yes/No 2.03 (1.70-2.43) <0.001 1.89 (1.58-2.23) <0.001 1.90 (1.59-2.27) <0.001
Smoking Yes/No 1.65 (1.39-1.95) <0.001 1.73 (1.46-2.05) <0.001 1.73 (1.45-2.05) <0.001
Diabetes Yes/No 2.57 (1.96-3.36) <0.001 2.38 (1.81-3.12) <0.001 2.38 (1.81-3.11) <0.001
Total Cholesterol 10 mg/dL 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001
HDL Cholesterol 10 mg/dL 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001
Current BP Treatment Yes/No 1.69 (1.41-2.03) <0.001 1.41 (1.16-1.73) <0.001 1.41 (1.16-1.72) <0.001
Current Dias BP 10 mm Hg 1.12 (1.03-1.22) 0.009 0.97 (0.87-1.08) 0.57
Ant Dias Bp 10 mm Hg 1.33 (1.20-1.48) <0.001 1.36 (1.20-1.54) <0.001
C Statistic 0.769 (0.752,0.787) 0.773 (0.755,0.791) 0.773 (0.755,0.791)
AIC Statistic 9586 9563 9565
Chi-square value 683 702 703
(a) Hazard ratio and confidence intervals
Performance Current + Antecedent Current + Antecedent
vs. Current vs. Antecedent
C Statistic Test p=0.07 p=0.40
IDI 0.004 (0.001,0.008) 0.000 (0.000,0.001)
Relative IDI 0.033 (0.008,0.059) 0.002 (-0.003,0.003)
NRI continuous 0.125 (0.034,0.214) -0.053 (-0.143,0.036)
NRI categories 0.054 (0.027,0.082) -0.003 (-0.013,0.007)
(b) Model comparison
Table 2.6: Mean Arterial Pulse Models
Units Current MAP Model Antecedent MAP Model Current + Antecedent MAP Model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age 1 year 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001 1.06 (1.05-1.07) <0.001
Male Yes/No 2.03 (1.70-2.43) <0.001 1.90 (1.59-2.27) <0.001 1.90 (1.59-2.27) <0.001
Smoking Yes/No 1.65 (1.39-1.95) <0.001 1.74 (1.46-2.06) <0.001 1.74 (1.46-2.06) <0.001
Diabetes Yes/No 2.51 (1.91-3.29) <0.001 2.29 (1.74-3.01) <0.001 2.29 (1.74-3.01) <0.001
Total Cholesterol 10 mg/dL 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001
HDL Cholesterol 10 mg/dL 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001 0.93 (0.90-0.96) <0.001
Current BP Treatment Yes/No 1.65 (1.37-1.99) <0.001 1.36 (1.11-1.67) <0.001 1.36 (1.10-1.67) 0.003
Current MAP 10 mm Hg 1.14 (1.05-1.23) 0.009 0.99 (0.90-1.09) 0.83
Ant MAP 10 mm Hg 1.31 (1.20-1.43) <0.001 1.36 (1.20-1.54) <0.001
C Statistic 0.771 (0.753,0.789) 0.775 (0.757,0.792) 0.775 (0.757,0.792)
AIC Statistic 9583 9559 9561
Chi-square value 688 712 712
(a) Hazard ratio and confidence intervals
Performance Current + Antecedent Current + Antecedent
vs. Current vs. Antecedent
C Statistic Test p=0.05 p=0.60
IDI 0.003 (-0.003,0.004) 0.000 (0.000,0.001)
Relative IDI 0.023 (-0.002,0.049) -0.001 (-0.001,0.001)
NRI continuous 0.161 (0.066,0.249) -0.068 (-0.165,0.016)
NRI categories 0.050 (0.023,0.076) 0.004 (-0.003,0.011)
(b) Model comparison
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When the models were run considering only hard CVD outcomes (death by CVD,
MI, and stroke), the results were similar but not statistically significant. This clas-
sification lead to a decreased number of events (389), which may explain the loss of
statistical power.
In a separate analysis that used Exam 5 as the baseline, we created a series
of models with increasing number of antecedent measurements, (in particular, with
2,3, and 4 measurements), and found no statistically significant difference in the
discrimination ability (the C-index values were 0.742, 0.744, and 0.745 for the three
models respectively, with no statistically significant difference).
2.4 Discussion
These findings show that antecedent systolic blood pressure is a statistically signif-
icant predictor of CVD. When antecedent pressure is added to a traditional risk
factor model, current BP becomes not statistically significant. The hazard ratio of
antecedent BP in both the antecedent and full models is greater than the effect seen
for current BP in the traditional risk factor model. An individual’s long-term expo-
sure to BP is a stronger predictor of CVD than the current pressure. A reasonable
conclusion is that long-term information related to blood pressure continues to be
relevant and higher BP levels in the past may exert long term effects on CVD risk.
Consistent with many previous studies and CVD risk scores [55], antihypertensive
treatment shows a positive association with risk for CVD, a seemingly contradictory
fact. In those studies, treatment may be acting as an indicator of higher blood
pressure in the past, which is consistent with our findings. The strength of current
BP as a CVD predictor diminishes when antecedent BP is introduced to the model.
In the multivariable Cox models, BP treatment has a hazard ratio of 1.66 in the
conventional model, and decreases to 1.43 in the full model. As antecedent BP is
added to the prediction models, more historical medical information is included for
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the individual. In our analyses the indicator variable for antecedent hypertension is
not significant in every model. This indicates that knowledge of whether a patient
has a history of hypertension is insufficient for the prediction models and the exact
pressure measurements are needed to demonstrate significant effects.
In the simple and multivariate models, net reclassification index shows significant
improvement in reclassification of individuals without events. This implies that the
full model has significantly better specificity than the conventional model. We would
not expect an improvement in sensitivity, since individuals with high risk scores in
the conventional model will continue to have high risk scores in the full model. How-
ever, individuals with intermediate risk scores may be reclassified downwards if they
have persistent BP at sub-hypertensive levels. These results must be clinically inter-
preted, but patients moving between tertiles of risk may be considered for different
treatments.
Our study does have limitations. The study population is predominantly white,
and may not be generalizable to other racial or ethnic groups. We only consider an-
tecedent BP as the simple average of two previously observed measurements. There
are other ways to incorporate historical BP. Considering a weighted average with
higher weights on more recent observations might perform better than simple av-
erage. An open question is how many years of antecedent information to consider.
Our secondary analysis suggests more measurements may improve the model, and
further results could quantify the added value of additional measurements. Future
work could consider using an exponential weighting scheme on previous observations,
incorporating all measurements and simplifying the choice of weightings to a single
parameter λ. In our primary models we have only 2 previous BP measurements and
are not able to evaluate the potential role of maximum BP attained over a length
of time, and other factors such as the age an individual first started treatment, the
duration of treatment, and whether treatment lowered the individual’s BP. We only
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consider antecedent BP as a risk factor, and could consider supplementing the model
with antecedent information of other risk factors such as cholesterol and smoking.
This study has demonstrated that antecedent systolic blood pressure is a statisti-
cally significant predictor of CVD. The clinical implication of the study is that blood
pressure levels in the past are highly associated with greater CVD risk. Clinicians
should ask patients about their BP levels in the past and potentially refer to previous
medical records, which will be possible with the widening use of electronic health
records and health information exchanges. Such patients with elevated antecedent
BP may be treated with a more aggressive BP lowering program with weight con-
trol, dietary advice, and medications. The latter possibility would most effectively
be evaluated with a clinical trial.
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CHAPTER 3
ANALYTICS APPROACH TO BLOOD PRESSURE CONTROL
3.1 Introduction
In chapter I, we discussed the health outcomes and cost associated with cardiovascular
disease. Elevated blood pressure (BP), referred to as hypertension, is a controllable
risk factor. Randomized control trials (RCTs), the gold standard of clinical evidence,
have provided abundant evidence that antihypertensive drug treatment can reduce
BP and improve health outcomes in patients with hypertension [43, 67]. Many anti-
hypertensive drugs are cheap, effective, and have minimal side effects. Based on the
existing RCTs, The Eighth Joint National Committee (JNC8) established the widely
adopted guidelines for when to initiate antihypertensive treatment [36], which suggest
initiating treatment in patients < 60 years old with SBP ≥ 140mm Hg or DBP ≥ 90
mm Hg.
While RCTs are powerful and provide strong evidence with respect to the scenar-
ios compared, they also have several inherent limitations. In particular, RCTs are
constrained in how many settings they can examine. When the number of potential
candidate scenarios/strategies is large, investigating each treatment option becomes
infeasible due to time, financial, and sample size limitations. Because of these lim-
itations, while BP progression through time and CVD risk depend on joint systolic
and diastolic BP, existing RCTs consider them independently and compare simple
strategies such as whether a systolic BP treatment initiation threshold of 130mm Hg
is superior to 140mm Hg. Second, due to the same inherent limitations, the exist-
ing RCTs of BP control only consider antihypertensive treatment initiation decisions,
but not treatment intensity/dosage decisions at various pressure levels. As a result,
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current guidelines do not offer suggestions on the intensity of treatment to initiate.
Instead, they suggest ad-hoc strategies, such as beginning with one drug and adding
more medications until the desired effect is obtained; however, it may be advanta-
geous to begin with a stronger drug regimen in patients with substantially elevated
BP to reduce BP and CVD event risk quicker. Finally, RCTs only examine primary
outcomes over a limited followup time and do not consider frequency of followup in
clinical practice. Evidence that one treatment option is preferred during the length of
the trial is not sufficient to guarantee that option is the best over a patient’s lifetime.
Antihypertensive treatment decisions should depend not just on present measure-
ments, but how frequently they may be observed in the future, which dictates how
many opportunities to initiate treatment exist. Intuitively, clinicians expecting to see
a patient frequently may adopt a more conservative treatment strategy than if they
see the patient infrequently, because in the former there are more opportunities to
initiate treatment if BP progresses adversely.
In this chapter, we propose a data-driven mathematical modeling-based approach
to a) study the joint effect of systolic and diastolic BP in optimal treatment initiation
decisions and b) characterize the optimal intensity of treatment at various BP levels.
We take a population-based approach and model blood pressure as a mixture of ge-
ometric Brownian motions, where mixture components correspond to progression of
blood pressure in different subpopulations. We analytically characterize the expected
value and variance of the hazard ratio which are used in computing the optimal treat-
ment decisions. We carefully calibrate and statistically validate our model using the
Framingham dataset and benchmark our findings against the current BP treatment
guidelines. Our data-driven model and findings can supplement RCTs in several ways
by providing additional evidence that may support the existing guidelines, or may
guide the design of future RCTs. Given that it is practically impossible to test all
plausible scenarios in RCTs, we believe such a data-driven modeling approach can be
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valuable in guiding future RCT development.
Our study also makes several unique contributions to the healthcare analytics and
management science literatures. First, while some earlier CVD risk prediction models
in the medical literature have considered the J-curve effect and joint effect of systolic
and diastolic BP [66], to our knowledge, our work presents the first prescriptive
modeling-based study capturing the joint effect of systolic and diastolic BP over time
and systematically analyzing the optimal thresholds at which to initiate and intensify
anti-hypertensive treatment. Second, unlike commonly used Markov decision process
models in disease modeling, our continuous space, continuous time mixture model
can be parametrized by arbitrarily timed observations, as commonly observed in
BP measurement. Third, our model can capture heterogeneity in population BP
progression. We find no simple distribution provides a good fit to real BP data,
while our proposed mixture distribution provides excellent fit. Fourth, unlike many
of the existing models commonly used in healthcare, our proposed approach provides
the hazard ratio and confidence intervals for each available treatment option, which
are often important for clinicians in decision making. These confidence intervals
allow practioners and patients to weigh the relative benefit of treatment options with
exogeneous factors such as patient preference, cost, cormobodities, and consideration
of possible adverse side effects. Last but not the least, our proposed approach provides
the hazard ratio and confidence intervals for each available treatment option and can
capture various attitudes towards risk, which are important in decision-making in
healthcare, but are commonly ignored by most existing studies.
We parameterize and validate our model using the Framingham dataset, one of the
largest and most credible longitudinal datasets for studying blood pressure changes
over time. We benchmark our findings against the current JNC8 treatment guidelines
and draw several policy implications. First, while the JNC8 guidelines consider sys-
tolic and diastolic pressure independently, we demonstrate that simultaneously con-
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sidering both pressure levels and their interdependent relationship may substantially
improve health outcomes. Second, we characterize the optimal systolic and diastolic
blood pressure levels for initiating treatment and intensifying dosage, which can be
helpful in reducing the variability in clinical practice. Third, our data-driven solutions
mostly corroborate current JNC8 guidelines if systolic and diastolic BP are treated
independently. Fourth, we find that when the interdependence of BP components
is considered, while patients with isolated systolic hypertension should be treated,
there might be tradeoffs associated with treating mild isolated diastolic hypertension.
Current guidelines suggest treating both cases of isolated hypertension, however, our
model indicates that the tradeoffs from the J-Curve effect favor not treating mild
isolated diastolic hypertension. These data-driven findings lead to testable hypothe-
ses which merit further empirical analysis and may motivate and guide the design of
future trials.
The remainder of this chapter is organized as follows. In §3.2, we review the
literature in medical decision making, blood pressure, and stochastic modeling, and
discuss our contributions to each. In §3.3, we introduce the model and provide analyt-
ical results. §3.4 describes the data and parameter estimation for the numerical study,
and §3.5 presents the results of the numerical study and confidence intervals. §3.6
presents sensitivity analysis, and §3.7 contains discussion, conclusions, limitations,
and suggestions for future work.
3.2 Literature Review
There are two broad literature areas relevant to our work: medical decision-making
studies dealing with long-term management for various chronic diseases and applica-
tions of continuous time stochastic processes in other domains.
The medical decision making literature concerning chronic disease management
over a long planning horizon typically models health state as a discrete time Markov
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chain and solves for optimal policies using a Markov decision process (MDP) frame-
work. [68] consider screening for breast cancer and [69] investigate biopsy referral
decisions for prostate cancer, both using a partially observable Markov decision pro-
cess (POMDP) personalized for individual patients. [70] develops and MDP model
for incorporating patient adherence to medication, along with individualized risk fac-
tors, to derive personalized optimal hypertension treatment planning strategies. MDP
models have also been used to find optimal treatment policies, including finding op-
timal timings of living donor liver transplantation [71] and related privacy concerns
[72], optimizing statin therapy in diabetic patients [73, 74], optimal HIV therapy [75],
antibiotic treatment in individuals with sepsis [76], and biopsy decisions in breast
cancer patients [77].
In the context of CVD, a few discrete-time Markovian models have been used,
mostly in the medical literature, to project long-term impact of current guidelines
with given BP treatment threshold levels, or to compare a small set of predefined
scenarios [78, 79, 80, 81]. In the management literature, [82] simultaneously optimize
systolic blood pressure and cholesterol treatment in diabetic patients, categorizing
systolic BP into low, medium, high, or very high states. [83] use a POMDP to per-
sonalize anticoagulation therapy to minimize the risk of stroke, considering individual
patients’ responses and sensitivity to treatment.[84] use an MDP to personalize the
optimal sequence of antihypertensive medications considering other risk factors such
as age, gender, and smoking. Other research has considered BP as a continuous mea-
sure and attempted to describe and predict trajectories of BP without providing a
probabilistic model of BP progression [85, 86]. [87] develops a dynamic programming
formulation for incorporating patient adherence to medication, along with individual-
ized risk factors, to derive personalized optimal systolic hypertension treatment plan-
ning strategies. Our work takes a different perspective, a population-based approach,
and differs from this study by considering systolic and diastolic pressure jointly and
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the tradeoffs associated with the J-curve effect, as well as considering heterogeneity in
BP progression with a mixture model. To our knowledge, this study presents the first
continuous longitudinal model of systolic and diastolic BP for assessing the optimal
thresholds at which to initiate and intensify anti-hypertensive treatment.
Markovian state models are appropriate when treating the thresholds as given,
but are insufficient for investigating optimal treatment thresholds of BP. For example,
considering systolic BP from 120 - 170 mm Hg and diastolic BP from 60 - 120 mm
Hg at every 1 mm Hg would result in a transition matrix with nearly 10 million
entries, estimation and analysis of which would be a major bottleneck. Parameterizing
such discrete-time Markovian models is typically infeasible, because as we discussed
earlier, BP is typically measured at arbitrarily-spaced time intervals, and existing BP
progression datasets reflect these irregular patterns.
Continuous time models have advantages over discrete time models in our ap-
plication. [88] discuss some of these advantages of continuous time models such as
providing physical insights into the system properties, handling non-uniformly sam-
pled data, and incorporating frequent observations. Specifically, when the sampling
is non-uniform, as may be case for blood pressure observations, estimation of discrete
time model parameters becomes more difficult [89]. Furthermore, studies have demon-
strated that continuous time methods may exhibit better predictive performance than
discrete time methods when applied to the same data sets [90]. Anticipating the data
challenges of Chapter IV, if for example an individual measures their BP twice in
a day, three days later, then one week after that, a continuous time model may be
better suited to handle these observations than a discrete time model.
Two closely related studies to ours are [91] and [92]. [91] combine machine learning
and optimization to predict effective combination of treatment regimens based on his-
torical trial results and help with designing future RCTs. While our work is similar to
[91] in the sense that our work also aims to inform the design of RCTs, the approaches
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and types of decisions analyzed are very different. In particular, while [91] consider
only end points such as survival and toxicity and attempts to identify promising drug
combinations, our approach explicitly captures the entire disease trajectory over time,
and aims to identify optimal treatment thresholds which depend on progression of
disease over time. On the other hand, [92] propose a bandit framework for learning
patients’ response types to treatment (e.g., responders vs. non-responders) over time,
and tailoring treatment to individuals based on their responses to prior treatments.
Although [92] apply their model to multiple sclerosis, their framework is applicable
to many chronic diseases where treatment is only effective for a subset of patients
(responders), and has serious side effects and hence could be harmful to others (non-
responders). While our study is similar to [92] in the sense that our work also aims to
optimize treatment strategies for a chronic condition, the two studies are different in
two key ways: 1) study perspectives and tradeoffs are different: while [92] take an in-
dividual patient’s perspective and aim to design personalized treatment strategies by
learning over time whether a patient is respondent or non-respondent to treatment,
we take a population perspective and aim to design population-based guidelines for
blood pressure treatment, such that the risk from high or low systolic and diastolic
BP is minimized, 2) underlying models and solution approaches are different: while
[92] formulate a Markovian model to capture disease progression model over time
and utilize multi-armed bandits for identifying optimal control strategies, we show
that a Markovian model cannot accurately capture BP change overtime, formulate a
Gaussian mixture model for capturing the underlying disease progression, and turn
our attention to Ito calculus for solution approaches.
While non-Markovian continuous time, continuous space stochastic processes are
common in financial literature [93, 94, 95, 96], they are utilized by only a handful
of studies in disease modeling and population health management literature. In that
context, two relevant studies to ours are [97] and [98]. [97] model glaucoma progression
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as a discrete time, continuous space process, more specifically a discrete time Gaussian
state space model, and develop a heuristic approach to find the time of next test to
detect glaucoma progression faster than seeing patients on fixed points in time (i.e.,
only monitoring). Using a similar framework, [98] extend [97] and jointly determine
the optimal monitoring regime and treatment such that a weighted sum of disease
progression cost, treatment cost, and testing cost is minimized. Our model differs from
these works in a few key ways. First, unlike [98] and [97], we model BP as a mixture
model, as our empirical analysis based on real data shows that no simple distribution
provides a good fit to BP data due to heterogeneity in disease progression. Second, the
models by [98] and [97] make monitoring and treatment decisions under the knowledge
that glaucoma progression is irreversible, while a blood pressure model must consider
the possibility that pressure will revert to a healthy state due to inherent variability or
factors other than antihypertensive treatment. Second, in those glaucoma progression
models, treatment decisions are based in part on cost and are assumed to cause
no harm. In other non-Markovian studies, [99] present a general stochastic model
building upon survival analysis to study screening strategies for patients on the kidney
transplant waiting list, with the objective of identifying patients who may develop
severe conditions while on the wait list, which makes them ineligible for transplant.
[100] use a continuous-time semi-Markov model to evaluate the cost effectiveness of
disease management programs for heart failure. [101] model progression of AIDS
biomarkers, specifically CD4 counts, using Ornstein-Uhlenbeck process, and study
a special case of their problem using a Brownian motion model. [102] develop a
stochastic model to analyze the health dynamics and management strategies of a
population in sub-Saharan Africa, where population health outcomes are captured
through a Markov-modulated Brownian motion model. [103] propose a LASSO bandit
algorithm and apply it to study the optimal warfarin dosage strategy based on a large
number of covariates, including patients’ clinical and genetic factors.
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3.3 Model and Analysis
An overview of the overall approach is as follows. First, we present a continuous time,
continuous space stochastic model to capture BP progression in §3.3.1. Second, we
estimate BP reduction from various treatment options in §3.3.2 and characterize the
hazard ratio function in §3.3.3. We define the optimization problem, derive closed-
form expressios for the mean and variance of the annual hazard ratio, and optimize
over treatment options in §3.3.4. Finally, we present our machine learning based
approximation of confidence intervals for hazard ratio in §3.3.5.
Notation used in this chapter is summarized on the following page.
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Average change in log blood pressure per unit time within each mixture
component i under natural disease progression
Reduction in log blood pressure from treatment k
during the first year and subsequent years, respectively
Covariance matrix of log blood pressure progression per unit time within each
mixture component i under natural disease progression
Change in covariance of log blood pressure progression from treatment k
during the first year and subsequent years, respectively
The Cholesky decomposition of a given covariance matrix Vi
Mixture weight of ith component Gaussian distribution
Log of population-level observed systolic and diastolic blood pressure at time t
Hazard ratio a patient with initial log BP X0 experiences over the
following T time if log BP evolves with mean µi and covariance Vi
Hazard ratio a patient with initial log BP X0 experiences over the
following T time when placed on anti-hypertensive treatment k
Minimum over available treatment options of expected hazard ratio
for a a patient with initial log BP X0 over the following T time
Parameters of the quadratic fit model of hazard ratio
Standard Brownian Motion
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3.3.1 A Model for Blood Pressure Progression
Our aim is to identify the optimal population-level BP treatment strategies and com-
pare our findings against the existing BP treatment guidelines, and for this purpose
we need to capture the progression of BP at the population level over time. Taking
a data-driven approach, we have considered various distributions to capture BP pro-
gression at the population level. Our empirical analysis based on the Framingham
data, one of the largest BP progression datasets in the US, has shown that BP pro-
gression in population is poorly fit by a simple distribution, but is well-captured by a
mixture distribution. Therefore, using the observed population-level data, we model
BP progression as a mixture distribution, where each patient is allowed to belong to
one or more of the mixture components, representing different subpopulations in the




log BP at time t; then the observed rate of change in BP in population-level data,




wi(µNi dt+ LNi dBt), (3.1)
where wi are the mixture weights, µNi are the mean change per unit time within
each mixture component under natural history progression, Bt is a standard 2-
dimensional Brownian motion, LNi is the lower triangular Cholesky decomposition
of the variance V Ni , namely, V Ni = LNi (LNi )










. We note that similar functional forms have been used in finance
[104] and climate research [105], and in addition to the statistical evidence we present
later (see §3.4), we remark that this model also makes physical sense: BP progression
is known to be heterogeneous across different subpopulations [106], and mixture com-
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ponents correspond to BP progression in different subpopulations. Finally, before
moving to the analyses, we reiterate that, similar to the existing BP management
guidelines, we take a policy-level perspective, rather than a clinical level perspective
of managing individual patients. However, while modeling the observed BP progres-
sion at the population level, this model also allows for capturing heterogeneity of BP
progression across subpopulations by allowing different means and variances of BP
changes in the overall population.
In the following proposition, we present the unique solution to Equation 4.1, which
allows us to capture the trajectory of the population-level BP change at any time in
the future, and is used in the calculation of hazard ratios.
Proposition 1. The unique solution to (3.1) is given by
Xt = X0 +
n∑
i=1
wi(µ̂it+ LNi Bt) (3.2)
where µ̂i = µNi − 12D(V
N
i ) and D(A) is the n× 1 vector of diagonal elements of A.
Proof. Ito’s lemma [107] in multiple dimensions states that for any twice differentiable














where Btj is the jth component of the Brownian Motion Bt. Take f(Xj, t) = Xt,j =
X0,jexp{(µNi,j − 12σ
2
i )t + LNi,jBt}, where Xt,j is the jth entry of the m × 1 vector Xt,




































Thus by Ito’s lemma we have









Ito’s lemma guarantees uniqueness of this solution.
The next proposition demonstrates that the change in BP per unit time follows





wig(x|µNi , V Ni ),
where x is a d-dimensional continuous vector, wi ≥ 0, i = 1, . . . , n are the mixture
weights where ∑ni=1wi = 1, and g(x|µNi , V Ni ), i = 1, . . . , n are d-variate Gaussian





′(V Ni )−1(x− µNi )}.
Proposition 2. The distribution of the increments of (3.2) is a Gaussian mixture
Z.
Proof. Let Ft and ft be the distribution and probability density functions of (3.1),
respectively, and let fi,t be the density of a mixture component. Then:
Ft(x) = P (Xt −X0 ≤ x) =
n∑
i=1
wiP (µ̂it+ LNi Bt ≤ x).














Therefore the density is the sum of Gaussian densities, and is therefore a Gaussian
mixture. This result can be seen as a multidimensional generalization of [104].
GMMs can form a smooth approximation to arbitrarily shaped densities [108]
making them appropriate for modeling change in BP. GMMs are frequently used
in finance due to their capability of representing a large class of sample distribu-
tions [109, 104, 110]. The complete model is parameterized by the mean vectors,
covariance matrices, and mixture weights, collectively represented by the notation
λ = {wi, µNi , V Ni }, i = 1, . . . , n and the parameters are estimated by an Expectation
Maximization algorithm [111].
We next show how to calculate the population parameter estimates from the com-
ponent distributions. Let Y be the mixture random variable, and Wi be the compo-
nent random variables. The mean µY and covariance ΣY of the mixture distribution











ΣY = E[(Y − E[Y ])(Y − E[Y ])


















The mixture mean is a weighted sum of the means of the component distributions,
and the mixture covariance is a weighted sum of the component covariances plus an
extra term to represent the shift to the new mean. Note that by Jensen’s inequality
the term ∑ni=1wiµiµ′i−µY µ′Y is non-negative. Thus, the mixture covariance is greater
than the weighted sum of the component covariances.
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3.3.2 Anti-hypertensive Treatment
In line with clinical practice, we consider a discrete number of antihypertensive treat-
ment options, each representing a possible dosage, including standard or half standard
dose of a one, two, or three drug combination. We allow the treatment effect in BP
reduction to follow any distribution with mean µRk and covariance V Rk , and also
possibly depend on initial log BP X0, but suppress this dependence on X0 for the
simplicity of the notation. As widely accepted and supported by clinical evidence
[112], in our base case analysis, we assume that the almost full potential effect of
blood pressure reduction from treatment is achieved within a year and after the first
year, remaining on treatment confers some relatively small adjustment to the progres-
sion under natural history with mean µPk and covariance V Pk . Later in our sensitivity
analysis, we consider various time lengths for initial treatment effect, and show that
our results are robust as long as benefit from treatment is achieved within the time
frame considered. Then, the expected BP change during the first year and the fol-
lowing years are captured by µ̇ki = µNi −µRk and µ̃ki = µNi −µPk respectively, and the




i=1wi(µ̇ki dt+ L̇ki dBt), for T ≤ 1∑n
i=1wi(µ̃ki dt+ L̃ki dBt), for T > 1
(3.5)
where L̇ki × (L̇ki )
′ = V̇ ki , V̇ ki = V Ni + V Rk ,L̃ki × (L̃ki )
′ = Ṽ ki , and Ṽ ki = V Ni + V Pk .
3.3.3 Characterization of the Hazard Ratios
The hazard ratio is a commonly used risk measure in the CVD literature, correspond-
ing to the increased chance of an adverse event from uncontrolled BP (e.g., mortality
or ESRD) compared to a patient with some reference BP, such as 135 mm Hg Systolic
BP and 85 mm Hg diastolic BP [113, 35]. The outcomes of drug studies in clinical
trials are frequently summarized by the use of hazard ratios because they make use
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of all available information, including patients who fail to complete the trial [113].
Prior studies in the clinical literature have shown empirically that a quadratic
model forms a quality approximation to the relationship between SBP/DBP and
hazard ratio (see Figure 1.1) [114]. Thus, we define the annual average hazard ratio
that patients initially at log BP X0 with annual drift µi and covariance Vi experience
over the following T years in reference to benchmark systolic and diastolic BP values
(135 mm Hg Systolic BP and 85 mm Hg diastolic BP, as:









Xt + c dt, (3.6)
where Xt is the stochastic process dXt = µidt + LidBt corresponding to a single
mixture of (4.1), and A ∈ R2×2, b ∈ R2 and c ∈ R are the best fit quadratic surface
from above.
3.3.4 Minimum Risk-Adjusted Hazard Ratio
We are interested in selecting treatment action k that minimizes the hazard ratio
patients at log BP X0 experience over the following T time units, which is defined as:
y(X0, T, k) =

∑n








−∞ fi,k,X0(x)HR(X0 + x, µ̃ki , Ṽ ki , T − 1)dx, for T > 1
(3.7)
where fi,k,X0(x) is the density function conditional on mixture component i of a
patient on treatment k initially at log BP X0 experiencing a change in BP of x in one
year. Equation (3.7) states that during the first year of treatment, patients experience
BP reduction according to the predicted reduction for the treatment and their initial
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BP [112], and after one year, continued use of the treatment offers some marginal
benefit over natural history progression captured in µPki and V Pki . As noted earlier, in
our sensitivity analysis, we consider various time lengths for initial treatment effect,
and show that our results are robust, as long as benefit from treatment is achieved
at some point within the planning horizon T. As such, in the calculation for T > 1,
we condition on the patient’s BP after one year and calculate the hazard ratio of the
remaining T − 1 years given this BP at year one. Then, the objective is to select
the treatment option that achieves the minimum expected hazard ratio over T years,
which is given by:
y∗(X0, T ) = min
k
E[y(X0, T, k)]. (3.8)
Alternatively, in order to capture different attitudes towards risk, we can also
consider a mean-variance optimization approach:
y∗(X0, T ) = min
k
(E[y(X0, T, k)] + λV ar[y(X0, T, k)]). (3.9)
where λ≥ 0 measures the degree of risk aversion: when λ = 0, (3.9) captures a risk-
neutral objective function; otherwise, the larger λ is, the more risk averse the decision
maker is. Mean-variance optimization models such as this are common in financial
studies [115, 116, 117]. We remark that the medical decision-making literature has
primarily taken a risk-neutral approach (see for example [82] and [75]), and our flexible
formulation and approach extends this literature by explicitly considering variation
in addition to expectation. In order to solve the model in (3.9), we need to know the
values of E[y(X0, T, k)] and V ar[y(X0, T, k)], which we analytically characterize.
We first present two lemmas that characterize the mean and variance of average



















where µ̂i = µi − 12D(Vi), D(A) is the n × 1 vector of diagonal elements of A, and
Tr(A) is the trace of the matrix A.
Proof: We first consider the case with a standard Brownian motion process. Sup-






′C1Bt + c2′tBt + c3′Bt dt.
We will first show E[U ] = T 22 Tr(C1). Since B(t) is a continuous function of t, U is
a Riemann integral with a random integrand. Therefore we calculate the expectation
and variance by Riemann sum approximations and take the limit.
For n > 0 let ∆n = Tn and tk = k∆n for k = 0, . . . , n. Using right Riemann sums,
the area under the curve from tk−1 to tk is approximated by





















By the independent increments property of Brownian motion, Bti −Bti−1 is inde-
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pendent of Btj−Btj−1 for all i 6= j, and the components of Bti−Bti−1 are elementwise
independent. Because increments are normally distributed, E[(Bti − Bti−1)j] = 0,
























































Now consider the general case:









Xt + c dt





(X0 + µ̂it+ LiBt)
′
A(X0 + µ̂it+ LiBt) + b



























X0 + c dt.
Using the specific case above with C1 = L
′
iALi, c2 = 2µ̂
′











































Noting that by properties of trace, Tr(L′iALi) = Tr(ALiL
′
i) = Tr(AVi), the desired
result follows.
Lemma 2.




















2V 2i ) + 5(µ̂i
′
ALi)












3 . By the independent increments property of Brownian
motion, Bti −Bti−1 is independent of Btj −Btj−1 for all i 6= j, and the components of
Bti−Bti−1 are elementwise independent. Because increments are normally distributed,
Var[(Bti − Bti−1)j] = ti − ti−1, Var[(Bti − Bti−1)j(Bti − Bti−1)l] = (ti − ti−1)2 and
Var[(Bti − Bti−1)2j ] = 2(ti − ti−1)2 for all i, j, and l. We furthermore observe that
Cov[(Bti −Bti−1)j, (Bti −Bti−1)2j ] = Cov[(Bti −Bti−1)j, (Bti −Bti−1)j(Bti −Bti−1)l] =
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((n− k + 1)c′3 + ∆n
∑n
i=k i · c
′
2)(Bti −Bti−1)
+(n− k + 1)(Bti −Bti−1)
′
C1(Bti −Bti−1)




Var[((n− k + 1)c′3 + ∆n
n∑
i=k




((n− k + 1)[c3]j + ∆n
n∑
i=k




((n− k + 1)[c3]j + ∆n
n∑
i=k















(n− k + 1)2[c3]2j + ∆2n(
n∑
i=k
i)2[c2]2j + 2∆n(n− k + 1)
n∑
i=k
i · [c2]j[c3]j, (3.11)
and


















([C1]j,l + [C1]l,j)2), (3.12)
and























j=1(n− k + 1)2[c3]2j + ∆2n(
∑n
i=k i)2[c2]2j
+2∆n(n− k + 1)
∑n
i=k i · [c2]j[c3]j
















































































To calculate variance of HR(X0, µi, Vi, T ):















(X0 + µ̂it+ LiBt)
′
A(X0 + µ̂it+ LiBt) + b
























X0 + c dt
Therefore









































Using the result with Y above, taking C1 = L
′
iALi, c2 = (2µ̂
′





Li), the result follows.
We are now ready to analytically calculate the values of E[y(X0, T, k)] and V ar[y(X0, T, k)]:
Theorem 3. The expected risk-adjusted hazard ratio that patients with initial log
BP X0 experience under treatment k (including no treatment) over T ≥ 1 years is
characterized by:





























i ) + 2(µ̄ki )
′
AX0 + bµ̄ki )











where µ̂ki = µ̇ki − 12D(V̇
k
i ), µ̄ki = µ̃ki − 12D(Ṽ
k
i ), and D(A) is the n×1 vector of diagonal
elements of A.
Proof. We first consider a single mixture component. From Lemma 1:
E[ 1
T
































fi,k,X0(x)HR(X0 + x, µ̃ki , Ṽ ki , T − 1) dx]




fi,k,X0(x)E[HR(X0 + x, µ̃ki , Ṽ ki , T − 1) dx].
By Lemma 1:
























A(X0 + x) + (X0 + x)
′
A(X0 + x) + b
′(X0 + x) + c
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dx


























fi,k,X0(x)((T − 1)(µ̄ki )
′




























+(T − 1)(µ̄ki )
′
Aµ̂ki + Tr(A(µ̂ki (µ̂ki )







Therefore combining (3.14) and (3.15) we have
E[ 1
T





fi,k,X0(x)HR(X0 + x, µ̃ki , Ṽ ki , T − 1)dx)]
=X ′0AX0 + b
′
X0 + c
+ 2T − 12T
(

















i ) + 2(µ̄ki )
′
AX0 + bµ̄ki )






Aµ̄ki + (µ̄ki )
′
Aµ̂ki (T − 1)
)
.
Summing the weighted mixture components produces the desired result.
Theorem 4. The variance of the risk-adjusted hazard ratio that patients with initial
log BP X0 experience under treatment k (including no treatment) over T ≥ 1 years
is characterized by:
























































+ 4(T − 1)3 Tr(A
2(V̇ ki )2)
+ (T − 1)
2
6 (2Tr(A
2(Ṽ ki )2) + 5((µ̃ki )
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AL̃ki )































fi,k,X0(x)V ar[HR(X0 + x, µ̃ki , Ṽ ki , T − 1)]dx
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= 56(T − 1)
2(µ̄′iAL̃ki )




















= 13(T − 1)
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+ 4Tr(A2(V̇ ki )2)
)
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The computational complexity of these calculations is low, requiring only arith-
metic and matrix multiplication.This implies that the model-based optimal dosage
decisions can be computed nearly instantaneously in a spreadsheet or other non-
specialized tool, which is very appealing from a practical perspective.
3.3.5 Approximate Confidence Intervals for Hazard Ratio
In this section, we present an approach for constructing confidence intervals on the
T-year hazard ratio experienced by patients under various treatment options. The tra-
ditional approach to constructing such intervals is to assume the quantity of interest
follows some known simple distribution and construct the intervals as a fixed number
of standard deviations above and below the sample mean. However, as we describe
in detail in the following paragraph, analytical and empirical evidence demonstrate
this approach is insufficient for our problem. As such, the remainder of this section
develops an accurate approximation to these confidence intervals.
In obtaining the expected hazard ratio in Theorem 2, we observed that the Brown-
ian increments (Bti−Bti−1)j are normally distributed, and therefore (Bti−Bti−1)2j has
a scaled chi-squared distribution. The distribution of a weighted sum of chi-squared
random variables has no analytical form [118], and since the hazard ratio is a gen-
eralization of this, it does not have a simple closed form distribution. Furthermore,
in our simulation model, the distribution of the hazard ratio was poorly fit by the
distributions considered (normal, lognormal, exponential, beta, and gamma). This
leads to poor fit of confidence intervals constructed by assuming a distributional form.
To address these challenges, we approximate the confidence interval bounds by ra-
dial basis functions (RBFs) [119]. RBFs are a method of multivariate approximation
/ interpolation for arbitrary functions that have been successfully applied in various
applications [120]. Given data points x1, x2, . . . , xn ∈ Rd, d > 1 and corresponding
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observations f1, f2, . . . , fn, the goal is finding a continuous function s(x) which ap-
proximates/interpolates the data well. RBFs construct s(x) as a linear combination
of basis functions, s(x) = ∑ni=1 αjθj(x). The weights αj are found by solving a sys-
tem of linear equations, equivalent to linear regression of the observations on the data
points.
For our basis functions we use the well known Wendland function [121] with
dimension d = 2 and smoothness k = 2. This function fits our data well and takes
the form
θj(x) = (1− r)6
(3 + 18r + 35r2)
1680
where r = ‖xj − x‖ is the Euclidean norm. The procedure is to first impose a mesh
on a range of BP values, each point of which corresponds to a basis function. We
chose Systolic from 110 to 170 mm Hg, and Diastolic from 50 to 120 mm Hg, dividing
that range evenly into 10 along each dimension (yielding 100 total basis functions).
At each point and for each treatment option, the hazard ratio is simulated for a large
number of replications, and the sample confidence interval bounds are recorded. The
weights αj in the linear combination above for lower or upper bound and a specific









θ1(x1) θ2(x1) . . . θn(x1)
θ1(x2) θ2(x2) . . . θn(x2)
... ... . . . ...








where fi is the simulated bound. Then for any point in the range of BP values, we
can construct an approximate confidence bound by calculating the basis functions
and taking the weighted sum.
The advantages of this approach are the high accuracy in approximation and the
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low computational effort to calculate the confidence interval bounds once the weights
have been solved. This calculation requires the weighted sum of 100 basis function
evaluations, a negligible computation time. These weights can be programmed in a
decision support tool and users can receive near instantaneous access to the confidence
bounds.
A disadvantage of this method is that it is less intuitive than normal approxima-
tions or other schemes that establish confidence interval bounds as a fixed number
of standard deviations above or below the mean. However, given the heavy-tailed
nature and the lack of fit to traditional distributions, we argue an intuitive approach
is insufficient and this more complicated method is necessary. Another disadvantage
is moderate apriori computational time to solve for the weights. For each mesh point,
a large sample must be simulated over the full time horizon, a non-trivial task. If
parameters of the model change, such as the hazard function or the population BP
dynamics, this simulation must be performed again to recalibrate new weights.
3.4 Data and Parameter Estimations
In this section, we describe our input datasets as well as the model parameterization
approaches and parameter values.
3.4.1 Blood Pressure Change: Gaussian Mixture Models
All parameters for the stochastic blood pressure models were fit from the Framing-
ham Heart Study, described in §1.1.2. The Framingham Original Cohort was chosen
instead of the Framingham Offspring Cohort because compared to the latter, the
former has more observations, smaller inter-observation times, and less confounding
due to treatment effects. This data set included 43,801 BP observations from 5,079
patients. BP readings at each exam were the average of two measurements to reduce
variability and measurement error. For each patient, BP readings at each exam and
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Table 3.2: Fitted Parameters for Systolic and Diastolic BP Gaussian 4-mixture model
Component wi (µNi )1 (µNi )2 (V Ni )11 (V Ni )12 (V Ni )22
1 0.4119 0.0046 -0.0005 0.0003 0.0002 0.0003
2 0.4079 0.0042 -0.0003 0.0005 0.0003 0.0005
3 0.1123 0.0021 -0.0044 0.0034 0.0022 0.0029
4 0.0679 0.0040 0.0012 0.0017 0.0009 0.0028
inter-observation times were recorded. No observations were recorded after a patient
experienced a CVD event or from patients above 70 years of age.
Based on the Framingham dataset, we find a Gaussian 4-mixture fits the systolic
and diastolic BP changes over time. The choice of n=4 mixture components has
the best AIC and BIC (Table 3.1 reports the fits of the Gaussian mixture model for
varying number of mixture components n). The estimated parameters of the best fit
mixture components are listed in Table 3.2. The mean and covariance of the change








As expected from clinical knowledge, the systolic component is increasing over time,
and disastolic is slightly decreasing over time.
3.4.2 Antihypertensive Treatment
The effects of drug treatment on BP progression were estimated from a meta-analysis
of 147 randomized trials [43]. They construct equations for the expected reduction
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in systolic and diastolic pressure resulting from different treatment options. They find:
"From the average blood pressure of 154 mm Hg systolic and
97 mm Hg diastolic, one drug at standard dose lowered blood
pressure by 9.1 mm Hg systolic and 5.5 mm Hg diastolic on
average. At lower or higher pretreatment blood pressures the
blood pressure reduction decreased (or increased) by 0.10 mm
Hg systolic and 0.11 mm Hg diastolic per mm Hg decrease (or
increase) in pretreatment blood pressure. . . . The estimated
blood pressure reduction for two or three drugs at standard
dose was calculated by applying these equations to each drug
in turn, allowing for the effect of the first in lowering
pretreatment blood pressure for the second, and the second for
the third. . . . Using drugs at half standard dose, taking dose
and pretreatment blood pressure into account, it was estimated
in the meta-analysis of 354 trials that one, two, and three
drugs at half standard dose reduced a pretreatment systolic
pressure of 150 mm Hg by 6.7 mm Hg, 13.3 mm Hg, and 19.9 mm Hg,
respectively, and reduced a pretreatment diastolic pressure of
90 mm Hg by 3.7 mm Hg, 7.3 mm Hg, and 10.7 mm Hg, respectively
(allowing for the effect of one drug in lowering pretreatment
blood pressure for the next). These blood pressure reductions
decreased (or increased) by an estimated 0.078 mm Hg systolic
and 0.088 mm Hg diastolic, per mm Hg decrease (or increase) in
pretreatment blood pressure per drug."
The authors therefore provide a recursive way of calculating blood pressure treat-
ment. To save on calculations, we derive a simple linear regression model for the BP
reduction at any pretreatment pressure which exactly fits their described effects by
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Table 3.3: Expected BP reductions for initiating treatment in a patient at pretreat-
ment SBP X, DBP Y
Systolic Reduction Diastolic Reduction
No Rx 0 0
1 drug, half dose .078X - 5 0.088Y - 4.22
1 drug, std dose 0.1X - 6.3 0.11Y - 5.17
2 drugs, half dose 0.156X - 10.1 0.176Y - 8.54
2 drugs, std dose 0.19X - 11.97 0.208Y - 9.77
3 drugs, half dose 0.234X - 15.2 0.264Y - 13.06
3 drugs, std dose 0.271X - 17.07 0.295Y - 13.87
without the need for recursive calculations. For example, for a patient at pretreatment
systolic X taking two drugs standard dose, we solve:
Red(X) = 9.1 + 0.1 ∗ (X − 154) +Red(NewPressure)
= 9.1 + 0.1 ∗ (X − 154) + (9.1 + 0.1 ∗ (X − (9.1 + 0.1(X − 154))− 154))
= 0.19X − 11.97
Table 3.3 gives the regression equations for the expected BP reductions for initiating
treatment in a patient with pretreatment systolic pressure X, diastolic pressure Y .
It is also necessary to generate equations for the effects of treatment reduction,
that is, switching to a less aggressive treatment. A patient with excessively low BP on
aggressive treatment may wish to switch to a less aggressive treatment, thereby raising
their BP. Since the BP reductions from initiating treatment are linear in pretreatment
pressure, the expected gain from reducing treatment has a unique solution. We
can calculate the effects of removing all treatment as follows: assume a patient’s
posttreatment BP is X, and we wish to solve for their pretreatment BP Z. Then
we can calculate X = Z −Red(Z). For example, a patient at posttreatment SBP X
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Table 3.4: Expected BP gain for removing all treatment in a patient at posttreatment
SBP X, DBP Y
Systolic Gain Diastolic Gain
No Rx 0 0
1 drug, half dose 0.085X - 5.42 0.096Y - 4.63
1 drug, std dose 0.111X - 7 0.124Y - 5.81
2 drugs, half dose 0.185X - 11.97 0.214Y - 10.36
2 drugs, std dose 0.235X - 14.78 0.263Y - 12.34
3 drugs, half dose 0.305X - 19.84 0.359Y - 17.74
3 drugs, std dose 0.372X - 23.42 0.418Y - 19.67
taking one half dose drug, we solve:
X = Z − (0.078Z − 5) = 0.922Z + 5
→ Z = X − 50.922
Therefore the expected gain is Z−X = 0.085X−5.42. Table 3.4 gives the regression
equations for the expected BP gain for removing all treatment in a patient with
posttreatment systolic pressure X, diastolic pressure Y .
To calculate the effects of switching from a more aggressive treatment k0 to a
less aggressive treatment k1, we first remove all influence of k0 by calculating the
pretreatment pressure using the equations in table 3.4, compute the posttreatment
pressure using the equations from table 3.3 and the calculated pretreatment pressure,
then compute the gain as the difference between the current pressure (on k0) and this
predicted pressure (on k1). To calculate the effects of a more aggressive treatment,
by linearity and the way the equations were constructed, it is sufficient to consider
current pressure and the addition of the difference in treatments. For example, for
a patient on 2 drugs standard dose, the BP reduction from switching to 3 drugs
standard dose can be calculated using current pressure and the equation for 1 drug
standard dose from table 3.3. Sample expected systolic BP reductions for a patient
currently on no treatment can be found in table 3.5, and diastolic in table 3.6.
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Table 3.5: Expected systolic BP reduction from antihypertensive treatment
Pretreatment One drug One drug Two drugs Two drugs Three drugs Three drugs
Systolic BP Half Dose Standard Dose Half Dose Standard Dose Half Dose Standard Dose
180 9.0 11.7 18.0 22.2 26.9 31.7
170 8.3 10.7 16.4 20.3 24.6 29.0
160 7.5 9.7 14.5 18.4 22.2 26.3
150 6.7 8.7 13.3 16.5 19.9 23.6
140 5.9 7.7 11.7 14.6 17.6 20.9
130 5.1 6.7 10.2 12.7 15.2 18.2
120 4.4 5.7 8.6 10.8 12.9 15.5
Table 3.6: Expected diastolic BP reduction from antihypertensive treatment
Pretreatment One drug One drug Two drugs Two drugs Three drugs Three drugs
Diastolic BP Half Dose Standard Dose Half Dose Standard Dose Half Dose Standard Dose
110 5.5 6.9 10.8 13.1 16.0 18.6
105 5 6.4 9.9 12.1 14.7 17.1
100 4.6 5.8 9.1 11.0 13.3 15.6
95 4.1 5.3 8.2 10.0 12.0 14.2
90 3.7 4.7 7.3 8.9 10.7 12.7
85 3.3 4.2 6.4 7.9 9.4 11.2
80 2.8 3.6 5.5 6.9 8.1 9.7
75 2.4 3.1 4.7 5.8 6.7 8.3
3.4.3 Hazard Ratio
Mortality and end-stage renal disease (ESRD), i.e. kidney failure, are two primary
outcomes resulting from uncontrolled hypertension [36]. We obtained hazard ratio
estimates for all cause mortality / ESRD from [35]. The study population included
398,419 treated hypertensive patients from the Kaiser Permanente Southern Califor-
nia health system. The average patient age was 64 years old, the population was
55% female, had mixed racial demographics, and had a variety of comorbidities. The
reported hazard ratios were adjusted for age, sex, race, body-mass index (BMI),
chronic kidney disease, diabetes, and cormobidities. Given this diversity in the study
population, the authors consider this study to be representative of a general hyper-
tensive population. The reported hazard ratios are listed in table 3.7, independently
for systolic and diastolic pressure. Following the conventions of that study, 135 mm
Hg systolic BP and 85 mm Hg diastolic BP were used as the reference pressures for
constructing the hazard ratios.
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Table 3.7: Hazard Ratio estimates from Sim et.al.
Systolic BP HR Diastolic BP HR
< 110 4.10 < 50 3.14
110-119 1.81 50-59 0.96
120 - 129 1.12 60 - 69 0.72
130 - 139 1.00 70 - 79 0.70
140 - 149 1.44 80 - 89 1.00
150 - 159 2.34 90 - 99 1.92
160 - 169 3.33 ≥ 100 3.83
≥ 170 4.91
We fit a quadratic model to log systolic BP and diastolic BP separately using
polynomial regression by randomly sampling from the reported hazard ratios. Specif-
ically, for each pressure category we uniformly generate a pressure within the category
and generate a hazard ratio as a normal random variable using the reported mean
and confidence intervals, and repeat for 1000 observations. The associated R2 values
were 0.911 and 0.82 respectively, indicating good fit of the models. We constructed
the fitted hazard ratio surface by averaging the hazard of systolic and diastolic pres-




Xt + [−238.05 −60.89]Xt + 710.7. We remark that averaging
of hazards is common in clinical practice [112], and in a supplemental study of §3.6
that jointly characterizes the hazards, we present statistical evidence showing that
the interaction effect is not significantly different from 0. The surface exhibits the
J-curve effect in both systolic and diastolic BP: for a fixed systolic BP, the minimum
hazard ratio is attained at some intermediate value of diastolic BP, and vice-versa.
3.4.4 External Validation
To assess the validity of our BP progression model on unseen data, we conducted an
external validation on the Framingham Offspring Cohort. This study began in 1971,
recruiting 5,124 relatives of the participants of the Framingham Original Cohort,
63
Figure 3.1: Fitted Hazard Ratio Surface
forming an independent population. 9,126 observations of blood pressure in non-
CVD patients not on antihypertensive treatment were recorded, and the observed
pressures in the population 4 years later were compared to the predictions from our
fitted model. For comparison, both observed and predicted pressures were binned
according to the categories reported in [35]. Figure 3.2 compares the observed and
predicted frequencies of the population systolic and diastolic pressures, and shows
that predicted values are close to the observed ones for both systolic and diastolic
blood pressures. Table 3.8 presents the joint pressure predictions and observations,
which also confirms the fit of our model.
In a supplementary analysis, we repeated the same procedure as above, but ex-
amining an 8 year validation window. Figure 3.3 shows this validation. We observe
that while the diastolic pressure prediction is accurate, our model underestimates
the true percentage of systolic pressure at the lowest category, less than 110 mm
Hg. Nonetheless, these differences are mild and we consider the model sufficiently
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In this section, we first discuss results about treatment initiation thresholds in §3.5.1
and treatment dosage intensification thresholds in §3.5.2. Then, we extend our results
to study treatment intensification and reduction decisions for patients currently on
treatment in §3.5.3. Next, we explore the implications of our treatment policy in
a simulation model in §3.5.4. Finally, we develop approximate confidence intervals
in §3.5.5. In our base case results, we take we take a risk-neutral perspective, as
population-based guidelines typically aim to minimize expected adverse events and
ignore variance ([122] and [123]). Later in §3.6, we also assess the sensitivity of our
base case results against different risk attitudes, as well as several other key model
parameters.
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Figure 3.3: 8 Year Validation of BP progression model predictions in external Fram-
ingham Offspring data
3.5.1 Treatment Initiation Thresholds
The thresholds for initiating one drug standard dose antihypertensive treatment in
patients currently on no treatment to minimize expected 10 year hazard ratio are
given in figure 3.4. 10 years was chosen because it is the standard prediction hori-
zon for cardiovascular disease risk calculators [124]. The dotted line shows the JNC 8
thresholds of systolic 140 and diastolic 90. We observe the optimal treatment decision
depends on both systolic and diastolic BP, and is nonlinear in both arguments. The
thresholds derived from our model are similar to the JNC8 thresholds, but differ in two
key ways. First, our findings imply that patients with systolic and diastolic pressure
medium-high should initiate treatment, even if not crossing the JNC thresholds. For
example, the results indicate that a patient with BP 135/85 should initiate treatment.
Second, while these results agree with JNC8 guidelines that patients with isolated sys-
tolic hypertension should initiate treatment, they suggest that mild isolated diastolic
hypertension should not be treated. For example, consider a patient with BP 120/95.
The current JNC8 guidelines, due to aforementioned inherent limitations of RCTs,
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Table 3.8: Comparison of joint Systolic / Diastolic BP in external Framingham Off-

































































































































treat systolic and diastolic BP independently by ignoring the interaction and joint
J-curve effect between the two and recommend treatment initiation for this patient as
their diastolic BP is greater than 90. On the other hand, our findings, which capture
this nonlinear effect, indicate that the benefits of reducing diastolic pressure in this
case are outweighed by the increase in risk from reducing systolic pressure due to
the J-curve effect. Given that it is not feasible to design RCTs to test all possible
scenarios, we believe such data-driven findings can help guide the design of future
antihypertensive treatment RCTs, and merit further empirical testing via trials.
To assess where the benefit from this policy primarily comes from, we examined
the distribution of blood pressure in the population and considered the 10 year hazards
cooresponding to the JNC8 policy or our policy. Specifically, we considered a one-
time decision of whether to initiate treatment or not initiate treatment and compared
the resulting hazard ratios. The average 10-year hazard was 1.437 under the JNC8










Optimal Treatment Initiation Thresholds
 
 










Figure 3.4: Optimal thresholds for initiation of treatment
Note. The dotted line shows the thresholds given by JNC8
down into two sources, the first arising from the additional treatment recommended
in medium-high systolic and diastolic patients below the JNC8 guidelines, and the
second coming from the cessation of treatment in patients with isolated diastolic
hypertension. We find 99.6% of the reduction in hazard comes from the former, with
only 0.4% of the reduction coming from the latter. This result follows from first, the
fact that medium-high systolic and diastolic pressure was common in the Framingham
data set, while isolated diastolic pressure was fairly uncommon; and second, a greater
reduction in hazard was observed for patients in the first region compared to reduction
in the isolated diastolic hypertension region. This indicates the improvement of our
treatment initiation policy primarily follows from the increased treatment in patients
with medium-high systolic and diastolic pressures.
3.5.2 Treatment Intensification Thresholds
In addition to treatment initiation thresholds, our proposed approach can also help
calculate the thresholds for the optimal drug dosages. Figure 3.5 shows the optimal
dosages for a patient currently on no antihypertensive medication. We make sev-
eral important observations from this figure. First, as would be expected, treatment
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1 drug half dose
1 drug standard dose
2 drugs half dose
2 drugs standard dose
3 drugs half dose
3 drugs standard dose
Figure 3.5: Optimal dosage intensification thresholds
sure. For a given systolic pressure, dosage increases as diastolic pressure increases,
and vice-versa. Second, optimal dosage usually tends to increase relatively quickly.
For example, for a patient with diastolic BP of 80, the weakest treatment (one drug
half dose) is initiated at systolic BP 130 and increases in dosage approximately every
5 mm Hg systolic. These dosage thresholds are the first such published results to our
knowledge, and can assist clinicians in determining optimal dosages to expediently
return patients to desirable BP ranges and reduce variation in clinical practice. In
particular, [125] reports high variability in clinical practice of hypertension manage-
ment owing, in part, to physician difficulty in integrating results from clinical findings
and doubts about improvement in outcomes from following guidelines. Our findings
may help in alleviating these concerns and lower variability in practice by providing
a framework to integrate findings about BP progression, antihypertensive treatment
effects, and risk of mortality as a function of BP.
3.5.3 Results for Patients Currently on Treatment
Our base case results presented above focus on patients not on treatment; however,
our modeling framework is flexible and can be also used in assisting with the optimal
dosage intensification or reduction decisions for patients on existing treatment, as
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illustrated below.
As noted in [112], intensifying (or reducing) treatment confers additional BP re-
duction (or gain) equal to the marginal difference in BP reduction from the two
treatments, adjusted for pretreatment pressure. These BP changes from treatment
can then be used in calculating the expectation and variance of hazard in Theorems
3 and 4. As an example, Figure 3.6 shows optimal treatment decisions for patients
currently on 1 drug, standard dose. The structure of the thresholds is very similar
to that of patients not currently on antihypertensive treatment, shifted to account
for the expected change in BP from removing or intensifying dosage. For example,
the risk of a patient with systolic BP 130 and diastolic BP 70 not currently on an-
tihypertensive treatment would be minimized by not initiating treatment. However,
a patient with the same pressures currently on 1 drug standard dose would minimize
risk by staying on 1 drug standard dose treatment, since reducing or removing this
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1 drug half dose
1 drug standard dose
2 drugs half dose
2 drugs standard dose
3 drugs half dose
3 drugs standard dose
Figure 3.6: Optimal dosage intensification thresholds for patients on 1 drug standard
dose
3.5.4 Simulation Model
To evaluate the performance of our policy against the baseline clinical guidelines
from JNC8, we created a simulation model of blood pressure progression. A patient’s
70
initial BP was randomly generated from a GMM of initial pressures, and a progression
mixture component is chosen based on the mixture weights. Their blood pressure
was simulated over 10 years using (3.2) to a discretization of 0.01 years. At 1 year
intervals starting at time 0 and proceeding through time 9, the patient’s BP was
observed and a treatment decision was made according to JNC8 guidelines or our
policy. One year decision intervals were chosen because blood pressure is typically
observed at annual physician checkups. The JNC8 policy initiates one drug standard
dose in untreated patients with systolic BP above 140 or diastolic BP above 90, or
intensifies treatment by one standard dose if patients are currently on treatment and
above these thresholds, up to a maximum of three drugs standard dose. Our policy
picks the treatment at each step that solves (3.8). Initiating or intensifying treatment
modified the simulated BP path according to the treatment equations in Tables 3.5
and 3.6. At the end of 10 years, the hazard ratio of the treatment-modified path was
calculated by integrating (3.6).
With 106 replications, the average hazard ratios following no treatment, the JNC8
policy, and our suggested policy were 2.197, 1.639 and 1.541, respectively. To put
these results into perspective, [38] estimate that use of antihypertensives prevented
86,000 premature deaths from cardiovascular disease in 2001. If these 86,000 deaths
are attributable to the reduction of hazard from 2.197 to 1.639 (an absolute reduction
of 0.558), the additional reduction of 0.098 from our policy could proportionally
prevent an estimated 15,100 premature deaths from cardiovascular disease annually.
However, we interpret these results cautiously. Clinical implementation of JNC8
guidelines may be more sophisticated than the written policy, for example, by allowing
reduction in treatment or implementing different dosages. Therefore actual gains from
our proposed policy may be more modest.
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3.5.5 Approximate Confidence Intervals for Hazard Ratio
See Figure 3.7 for a histogram of the simulated distribution of the 10-year hazard
ratio 20,000 patients initially at BP 150/100 on two drug standard dose treatment.
This heavy tailed distribution is poorly fit by all standard distributions considered
(exponential, beta, lognormal, gamma). Figure 3.8 shows the associated QQ plot
for fitting a normal distribution, demonstrating serious deviations from normality. It
may be reasonable to believe that even if the distribution is poorly fit by a normal
distribution, the resulting confidence intervals may still be accurate. The most easily
recognizable confidence interval is of the form µHR ± zα/2σHR, which assumes the
distribution of hazard ratio is normal. This assumption is frequently made in practice,
so we attempt to construct such an interval, despite a proof that hazard ratio is not
normally distributed. On the training data of 100 points, we compute the mean and
variance given by the theorems above, and simulate the hazard ratio many times to
calculate the exact upper and lower α confidence intervals. We then optimize z to
minimize the average error in the hazard ratio approximation. Our numerical results
for 95% confidence intervals find the optimal value of z is 1.174. However, on the
test data, this choice of z gives an average error of 12.2%. For example, for a patient
with BP 150/90 taking no treatment, the mean hazard ratio is 2.136 and standard
deviation is 1.12. The exact lower confidence bound is 0.930, and the predicted bound
using the above formulation is 0.821, a 11.7% error.
The confidence interval approximation by RBFs is accurate. On a training set
of 100 points forming a grid of systolic and diastolic pressures, the approximation of
lower and upper bounds have a relative error < 0.01% for all treatment options. On
a test set of 20 points sampled uniformly at random from the BP range, Table 3.9
shows the resulting approximation errors. The average relative error in approximat-
ing the lower bound was 0.84% across all samples, and 3.64% for the upper bound.
Figure 3.9 shows the upper and lower 95% confidence bounds over a range of systolic
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Table 3.9: Relative error in approximation of 95% confidence interval bounds across
randomly sampled test data















Lower Bound 0.96% 0.89% 0.80% 0.72% 0.78% 0.84% 0.88% 0.84%
Upper Bound 2.88% 3.37% 3.47% 3.75% 3.93% 3.96% 4.14% 3.64%
pressures for a patient with diastolic BP 90 undergoing treatment of two drugs, stan-
dard dose. From these results, we conclude these approximate confidence intervals
are computationally efficient and may provide additional evidence to assist users in
decision making.
Figure 3.7: Histogram of simulated hazard ratios, initial BP 150/100
3.6 Sensitivity Analysis
In this section, we assess the sensitivity of our findings against key model parameters,
including the hazard ratio, BP progression rate, risk behavior, BP measurements,
treatment effect, time to achieve treatment effect, and planning horizon.
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Figure 3.8: QQ plot of simulated hazard ratios, initial BP 150/100
3.6.1 Sensitivity to Hazard Ratio
To assess the sensitivity of our policy against perturbations in the hazard ratio, we
conducted a sensitivity analysis by perturbing the reported hazard ratios by up to
±25% . More specifically, in each replication, each hazard ratio for different BP values
was multiplied by a uniformly distributed random variable to generate hazard ratios
between plus or minus 25% of the reported value. The best fit quadratic model of
these perturbed hazards was used as the true hazard, and treatment decisions were
made according to our policy described in §3.5.2. With 1000 replications, the relative
loss in achieved hazard averaged across population BP levels was 0.17%, indicating
our model performs well even under moderately misspecified hazards.
While robust against moderately misspecified hazards, the performance of our
policy may suffer if the shape of the hazard surface is drastically different. Studies
reporting a stronger J-curve effect suggest less aggressive treatment, as the potential
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Figure 3.9: Simulated and exact confidence interval bounds for a patient with diastolic
BP 90 taking two drugs, standard dose
harms from over-treatment are greater [24]. To examine the model solution under
a different parameterization of the hazard ratio surface, we obtain hazard ratio es-
timates for all cause mortality/ ESRD from [126]. That study followed 651,749 US
Veterans with chronic kidney disease (CKD) for a median follow-up of 5.8 years. In
comparison to the main result study population, this population is older (average
age 73.8 years), almost exclusively male (97.3% male), and each patient suffers from
a specific cormobidity. Therefore this study is not appropriate for drawing popula-
tion level conclusions, but instead to demonstrate the capacity of our model for easy
adoption to new data and its power in application to subpopulations. It is further of
interest because they provide hazard ratio estimates based jointly on systolic and di-
astolic BP. Table 3.10 lists the hazard ratios associated with categories of systolic and
diastolic BP, and Figure 3.10 for the fitted surface. The fitted hazard ratio function
exhibits the J-curve effect more intensely than that in our primary analysis. In fact,
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from the data and subsequent parametrization, we observe higher risk for patients at
the lowest categories of pressure than at the highest categories.
The optimal intensification thresholds under this parametrization are given in
Figure 3.11. These results differ considerably from the main results. The policy is
more conservative than in our primary results. This is expected due to the stronger
J-curve effect. Patients suffering from CKD can suffer physiological damage from
excessively low blood pressure owing to arterial stiffness [127], so it is consistent
that hypertension treatment should only be applied in patients with excessively high
pressures. Using our policy to make treatment decisions in this subpopulation resulted
in a relative error of 3.23%, unacceptably high. This emphasizes the importance
of ensuring the correct shape of the hazard ration surface in the population being
studied.
Table 3.10: Hazard ratios for all cause mortality associated with Systolic and Diastolic
BP in patients with CKD. Source: [30]
80 ≤ 90 ≤ 100 ≤ 110 ≤ 120 ≤ 130 ≤ 140 ≤ 150 ≤ 160 ≤ 170 ≤ 180 ≤ 190 ≤ 200 ≤ 210 ≥
SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP SBP
<80 <90 <100 <110 <120 <130 <140 <150 <160 <170 <180 <190 <200 <210
DBP <40 2.56 2.42 2.55 2.15 1.73 1.69 1.91 - - - - - - - -
40 ≤ DBP <50 2.99 2.69 2.31 1.77 1.58 1.39 1.37 1.30 1.50 1.83 - - - - -
50 ≤ DBP <60 3.25 2.88 2.24 1.77 1.51 1.27 1.14 1.17 1.27 1.32 1.63 1.20 - - -
60 ≤ DBP <70 - 3.11 2.32 1.82 1.48 1.23 1.09 1.09 1.12 1.13 1.28 1.36 1.00 - -
70 ≤ DBP <80 - - 2.05 1.70 1.34 1.14 1.01 1.01 1.04 1.07 1.12 1.19 1.11 1.17 1.26
80 ≤ DBP <90 - - - 1.82 1.27 1.08 0.98 1.00 1.01 1.07 1.13 1.22 1.43 1.25 1.35
90 ≤ DBP <100 - - - - 1.57 1.26 1.08 1.10 1.15 1.18 1.25 1.23 1.16 1.38 1.04
100 ≤ DBP <110 - - - - - - 1.53 1.16 1.31 1.33 1.37 1.30 1.62 1.40 1.42
110 ≤ DBP <120 - - - - - - - - 1.11 1.28 1.81 1.35 1.89 1.85 1.71
DBP ≥ 120 - - - - - - - - - - 1.62 - - 2.44 2.06
3.6.2 Sensitivity to BP Progression
To quantify the sensitivity of the optimal policy against the estimate of mean BP
progression, we considered increasing the mean of each mixture component by 25%
and assessed the performance of our policy compared to the true optimal treatment
policies. The resulting treatment policy is visually depicted in Figure 3.12, and treat-
ment decisions made according to our policy induced average relative loss in achieved
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Figure 3.10: Fitted hazard ratio surface. Data source: [30]
hazard of 0.027%, indicating that our model is robust against moderately misspecified
estimates of mean BP progression.
In the following proposition, we show that the optimal treatment strategy does
not depend on the mixture covariance V Ni . The intuition behind this result is that
treatment affects the BP level but not the variability in progression, hence optimal
treatment decisions are not impacted by the covariance of BP progression.
Proposition 3. Under a risk-neutral perspective (λ = 0), as the inter-observational
blood pressure variance V Ni changes, there is no change in the difference between the
expected hazard ratios of treatment k1 and treatment k2.
Proof. Using Theorem 3, the difference in expected T-year hazard ratio between two
treatments k1 and k2 for a patient at log BP X0 is
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1 drug half dose
1 drug standard dose
2 drugs half dose
2 drugs standard dose
3 drugs half dose
3 drugs standard dose
Figure 3.12: Optimal intensification thresholds with BP progression 25% higher than
estimated
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To examine the sensitivity of the optimal solution to the mixture covariance V Ni ,
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That is, the expected hazard ratio does not depend on V Ni .
The implication of this result is that the scale and shape of variance in blood
pressure change does not affect the optimal solution in a given population under a
risk-neutral perspective. We remark that this result would not hold under a risk
averse perspective (λ > 0), as the variance of risk is affected by treatment deci-
sion. We further remark that this is a simple yet powerful result, because population
based guidelines typically take an expectation minimization/maximization approach
and ignore variance(See for example population-based cancer screening guidelines
by recommended CISNET simulation models (cisnet.gov), which influenced clinical
guidelines). The intuition behind this result is that treatment affects the BP level but
not the variability in progression, hence optimal treatment decisions are not impacted
by the covariance of BP progression.
3.6.3 Sensitivity to the Risk Behavior
In our main analysis we adopted a risk-neutral perspective, where λ = 0. Here we
consider how the treatment decisions depend on the choice of the risk consideration λ.
Figure 3.13 demonstrates the optimal decisions when the objective to be minimized is
an equal weighting of mean and variance of hazard (λ = 1). We observe that overall
the results are similar to our main risk neutral results, with slightly more aggressive
treatment in patients with isolated systolic pressure and less aggressive treatment in
patients with isolated diastolic pressure. For example, under a risk neutral decision, a
patient with Systolic BP 110 and Diastolic BP 105 would be advised to begin one drug
half dose, while under the λ = 1 perspective the same patient would be advised not
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to initiate treatment. Intuitively, the decisions are not very different because from
Figure 3.1, we observe that regions with smaller hazard also tend to have smaller
variability in hazard. While this holds for BP management, in other applications
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1 drug half dose
1 drug standard dose
2 drugs half dose
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3 drugs standard dose
Figure 3.13: Optimal intensification thresholds with λ = 1
3.6.4 Sensitivity to Blood Pressure Measurements
We consider how our policy performs if the measurement of current BP is incorrect.
White-coat hypertension is a phenomenon where BP observed in clinical settings can
be up to 5 mm Hg higher than true pressure in both systolic and diastolic compo-
nents [128]. Our analysis shows that our results are sensitive to BP readings and that
using our policy to make treatment decisions in these patients would lead to overly
aggressive treatment decisions because of the overestimation of current pressure. Fur-
thermore, the treatment effects in this case would also be miscalculated because the
reduction from treatment depend on initial pressure. The treatment decisions made
according to our policy induced average relative losses in achieved hazard of 1.75%,
emphasizing the importance of the guideline’s recommendation of confirming true BP
before initiating treatment [36].
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3.6.5 Sensitivity to Treatment Effect
To assess our policy against sensitivity to benefit from treatment, we considered
increasing and decreasing the cumulative BP reduction from each treatment option
by 25%. The resulting optimal policies are given in Figures 3.14 and 3.15, and the
resulting losses in relative hazard are 0.86% and 0.51% respectively, indicating our
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1 drug half dose
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1 drug half dose
1 drug standard dose
2 drugs half dose
2 drugs standard dose
3 drugs half dose
3 drugs standard dose
Figure 3.15: Optimal treatment decisions, treatment effect - 25%
3.6.6 Sensitivity to Length of Time to Achieve Treatment Benefit
In our main analysis we assume the almost full benefit of treatment is achieved within
one year. Here we consider how the treatment decisions perform if the BP reduction
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is instead achieved within different time intervals, anywhere within 3 months to 5
years. While we consider a wide range, here we only present the two extreme cases,
corresponding to within 3 months and 5 years treatment benefit effect in Figures
3.16 and 3.17, respectively. Comparing these results with our base case results shows
them to be quite similar. The corresponding losses in relative hazard are 0.004% and
0.13%, indicating that the time to achieve benefit of treatment is not critical to the
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1 drug half dose
1 drug standard dose
2 drugs half dose
2 drugs standard dose
3 drugs half dose
3 drugs standard dose
Figure 3.17: Optimal treatment decisions, treatment occurring in 5 years
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Figure 3.18: Optimal treatment decisions, T=1.
Figure 3.19: Optimal treatment decisions. T=5.
3.6.7 Sensitivity to Planning Horizon T
We find little change in treatment decision as the planning horizon T changes. For
example, Figures 3.18 and 3.19 compare the optimal treatment policy under planning
horizons T = 1 and T = 5 respectively, where we observe some small differences in the
thresholds for initiating various treatment options, but overall the policy is similar as
under the base case with T = 10. Treatment decisions made according to our policy
induced average relative losses in achieved hazard of 0.26% and 0.04%, respectively.
Therefore, we conclude that our results are not very sensitive to the planning horizon
T .
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3.7 Discussion and Conclusion
Among the principles recommended by the American Heart Associaton, the American
College of Cardiology, and the Centers for Disease Control for creating an effective
hypertension management algorithm are the following four [129]. First, to base the
algorithm on best available science. Second, format the algorithm to be simple to
update as better information becomes available. Third, the algorithm should have a
feasible, simple implementation strategy. Finally, it should be developed in a format
able to be incorporated into electronic health records for use as a clinical decision
support tool.
Our model meets all of these recommendations. First, it has been built on the
best available science, incorporating the best known results about BP change over
time, risk of cardiovascular disease for a given BP, and the effects of antihypertensive
treatment. Second, our model is simple to update as better information emerges.
The expected average T -year hazard ratio is a simple arithmetic function of the pa-
rameterizations. If new data become available, the fitted parameters only need to be
recalculated and optimal thresholds can be solved using Theorem 3. The model is
easily updateable for new estimates of BP progression, CVD hazard ratio, or antihy-
pertensive treatment benefit. This ease of calculation is a major advantage over MDP
models that would require implementing the process and resolving if new information
became available, a process requiring specialized expertise and significant computa-
tional effort. As mentioned previously, this algorithm is simple to implement. Despite
the visual complexity of the expression of the expected hazard ratio in Theorem 3, it
is a simple arithmetic expression. Calculation of the expected hazard ratio and 95%
confidence interval using the radial basis function approach for each treatment option
is near instantaneous on any modern computer. Finally, this algorithm can easily be
incorporated into electronic health records as a decision support tool. Because of the
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simplicity of calculation, any programming language or spreadsheet can calculate the
hazard ratios for each treatment option. We stress that the calculation of confidence
intervals makes this a decision support tool, and not a decision maker. Clinicians can
weigh the relative benefit of each treatment against exogenous information such as
patient preference, cost of treatment, comorbidities, and risk of side effects.
Our findings can help guide the design of future antihypertensive treatment RCTs.
Given that it is not feasible to test all possible scenarios in RCT settings, our data-
driven methods may prove helpful in identifying the promising scenarios, which could
then be tested empirically through actual trials. In particular, our findings of a)
initiation and intensification thresholds depending jointly on systolic and diastolic
pressure, b) intensification thresholds standardizing clinical practice, and c) tradeoffs
associated with treating mild isolated diastolic hypertension merit testing by RCTs,
the gold standard of evidence. Specifically, our results indicate that a trial comparing
outcomes in treated and untreated patients at moderate-high systolic and diastolic
pressure but below JNC8 guidelines, such as 135/85, may yield benefit. Similarly, our
treatment intensification thresholds suggest that patients at 145/90 should initiate 2
drugs standard dose, so this policy could be compared to initiating 1 drug standard
dose as prescribed by JNC8. Such trials may provide evidence to verify our findings
and improve health outcomes.
3.7.1 Limitations
Our work has various limitations due to data availability and necessary assumptions
for computational tractability. Our parameterization of blood pressure change is
based on the Framingham study, an older data source. This was necessary because it
is the only clinical trial with longitudinal BP observations. In particular, we demon-
strated that the change in BP per unit time is well modeled by a Gaussian mixture,
but the majority of our inter-observation times were 2 year intervals. Therefore we
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are unable to establish the model (3.1) is valid for all inter-observation times. The ex-
pectation maximization algorithm used to fit the GMM returns only a local solution.
In particular, running the algorithm with different initial solutions or random seed
results in different component mixtures. However, the mean and variance of the mix-
ture distribution remains nearly the same, which are the only important features for
our calculations. In addition, the model that we propose is general and can be easily
recalibrated using other comprehensive datasets or subpopulations as they become
available in the future.
Our assumption of perfect knowledge of blood pressure requires clinicians to take
repeated measurements before implementing our solutions. This is simple to satisfy,
as blood pressure would be measured several times in clinic or with an at home device
to gather an accurate estimate before an antihypertensive regiment was initiated. All
Framingham measurements were averages of several observation, so our progression
model is built on perfect measurements of BP. This limitation does make the threshold
inappropriate for use as a screening tool.
We have assumed hazard ratio is well fit by a second degree quadratic surface for
computational tractability, and demonstrated sufficient statistical fit. Higher degree
surfaces would render the necessary stochastic calculus calculations unwiedly. Our
calculation of the average expected T -year hazard ratio assumes no future actions
may be taken. Specifically, it assumes treatment must be initiated today or not at
all. While this is a limitation, cardiovascular disease risk calculators adopt this same
assumption, predicting 10-year risk based only on present measurements. In addition,
we demonstrate in the simulation model that our policy outperforms existing clinical
guidelines, even when future actions are possible.
In this study we optimized treatment decisions based solely on hazard ratio. Cost
of treatment was not considered because it is extremely low. One year of generic
BP treatment is estimated at $212 and one cardiovascular event costs over $ 10000
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in hospitalization, rehabilitation, and long-term care [39], so even small reductions
in risk are cost effective. The major trade-off considered is increased hazard ratio
from over aggressive BP reduction due to the J-curve effect. Other side effects of BP
treatment such as dizziness or fainting [131] and diuretic induced low potassium levels
[132] should be considered qualitatively by practitioners when comparing the relative
benefits of different treatment options and their associated confidence intervals.
3.7.2 Future Work and Conclusion
Future work should expand this model to include personalizable results. Currently,
this model uses population level estimates of drift and variance of BP change. Algo-
rithms that track an individual’s BP and forecast future progression can be imbedded
within our main result as an improvement over population level estimates. Such an
algorithm could monitor trends within an individual and predict, for example, when
a patient with presently controlled BP may be rapidly increasing and therefore wish
to initiate treatment. Such algorithms could accommodate unequally spaced obser-
vations and could incorporate information from office, home, and ambulatory mea-
surements. Future work could also consider applying this model to other continuous
state health measurements with available control strategies, such as cholesterol, blood
glucose level in diabetics, or body mass index.
We have presented a model that aids in the decision of initiating anti-hypertensive
treatment. For a given current BP, the model exactly calculates the mean and vari-
ance of the average hazard ratio a patient will experience over the following T years
under various treatment options. The model optimizes treatment by picking the treat-
ment that results in the lowest risk adjusted hazard ratio. In addition, it calculates
approximate confidence intervals so decision makers can weigh the relative benefits
of treatment with exogenous information. The advantages of this model are the flex-
ibility of handling BP as a continuous time, continuous state process, the simplicity
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of calculation, and the ease of updating the model with new data. We hope this work
may inspire future work in mathematical models of continuous health measurements.
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CHAPTER 4
PERSONALIZED BLOOD PRESSURE MANAGEMENT
4.1 Introduction
Personalized medicine has become a prominent topic in recent history for its poten-
tial value to public health [133, 134, 135]. The term “personalized medicine” broadly
refers to providing care according to the individual patient’s susceptibility to a dis-
ease, rate of disease progression, and response to specific treatment options [136].
Population level guidelines are built on aggregated results from randomized control
trials. Yet, it is recognized that individuals respond differently to treatment due to
biological, behavior, and life history characteristics [133]. With advances in big data,
computational power, and algorithms, researchers and practitioners have recognized
the value in personalized approaches in the management of chronic diseases.
In Chapter I, we discussed how wearables and other devices associated with the In-
ternet of Things, collectively known as mobile health (mHealth), have the potential to
revolutionize the management of chronic disease. Fitness trackers and smart watches
measure and record vital measurements (VMs) such as pulse, heart rate variability,
blood oxygenation, and blood sugar. In January 2018, Omron Healthcare debuted a
wearable BP monitor that will enter the marketplace fall 2018 [50]. New mHealth de-
vices offer access to unprecedented amounts of individual, patient-level data that are
recorded at short intervals. Many of these technologies integrate with smartphones
to provide data tracking and visualization. However, the analytics potential of these
data remains largely unexplored [52].
As discussed in Chapter I, CVD is the leading cause of death both in the United
States and worldwide [137] and has many controllable risk factors; therefore it is one
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of the largest areas in which mHealth can improve health care [138]. Traditionally,
BP was measured at annual clinical examinations and treatment was initiated in
patients above a threshold value [36]. With the rise of mHealth, new opportunities
exist for screening and monitoring BP in non-clinical settings [46]. In addition to the
existing devices mentioned above, it is anticipated that by 2020 more wearables may
be capable of blood pressure monitoring [51]. For these reasons, BP is an excellent
candidate to study in an analytics framework. In this chapter we design analytics
based tools and approaches for BP monitoring. While designed primarily for BP
monitoring, we believe our proposed approaches could be generalizable to a variety
of VMs.
A concern from the health community about mHealth is their highly noisy mea-
surements due to mis-calibration or improper user training. For example, [139] found
30% of home blood pressure monitors exceeded 5 mm Hg error on average and were
declared inaccurate according to FDA regulations. The problem is exacerbated by
wearables - examining a popular unregulated consumer smartphone app for measur-
ing BP, [140] found the mean absolute difference between true and reported BP was
12.4 mm Hg, which they refer to as ‘highly inaccurate’. While this is problematic for
single uses of such technology, as long as the noise is unbiased (or we know the dis-
tribution of the noise), this problem is alleviated by the large number of observations
typically collected by mHealth. Observations at the daily level, as provided by wear-
ables and other technologies, can still provide accurate information about the VM
when aggregated. Highly noisy daily measurements can lead to effective monitoring
policies when statistical tests are designed to balance Type I/Type II errors.
In this chapter we propose statistical and mathematical methods that use measure-
ments from wearables and other technologies to make screening decisions for chronic
diseases. We propose changepoint detection-based algorithms that signal when the
likelihood the VM of interest has exceeded some threshold value is high. Such a
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signal may suggest the user follow up with a clinician for diagnosis and treatment
options (for example, in the case of blood pressure or cholesterol) or take immediate
action (for example, an elevated heart rate or low blood glucose level). We first de-
sign a Bayesian belief-based changepoint method that uses knowledge of the disease
progression. Then, we develop a Naive changepoint procedure that is simpler and
is applicable to a wide variety of VMs. Finally, we demonstrate the effectiveness of
our algorithms on simulated blood pressure data and show the improvement in our
algorithm over benchmark policies.
4.2 Literature Review
There are three broad literature areas relevant to our work: wearables, internet of
things, and other emerging technologies for VMs; personalized screening in chronic
diseases; and statistical process control and changepoint detection.
The medical community is cautiously optimistic about the potential of wearables
to improve health in chronic disease populations [141, 142]. Studies demonstrating
successes have included physical activity monitoring in patients with multiple scle-
rosis [143], rehabilitation in individuals with chronic conditions [144], obesity track-
ing [145], and heart failure self-care [146]. In a review of existing mobile apps, the
American Heart Association (AHA) found “the evidence ... clearly demonstrates the
great potential that mobile technologies can have” in cardiovascular disease preven-
tion [147], yet they also found a lack of scientific rigor in evaluating the algorithms
and technologies. In a recommendation on telehealth, the AHA said “the future of
healthcare delivery will likely involve increased reliance on mobile computing (e.g.,
smartphones) that can support a variety of operating systems and healthcare appli-
cations (e.g., FDA-approved blood pressure monitors)” [148]. Reviews have remarked
that “mobile health technologies offer promise with regard to the management and
prevention of cardiovascular disease via risk factor modification” [149] and suggested
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future research explore analytical methods for data analysis [150].
Personalized medicine has the potential to improve public health in the screening,
monitoring, and treating of chronic disease [133, 134, 135]. Within cardiology, [151]
uses a personalized chronotherapy approach to informing patients when throughout
the day to take their antihypertensive treatment to achieve maximum BP reduc-
tion. [152] predict when a patient will attain or leave hypertension control based on
current BP and comorbid conditions. [153] propose making treatment decisions for
individuals on the basis of the difference in 10-year risk score taking or not taking an-
tihypertensive treatment. [154] uses a Markov modeling approach and an imbedded
risk score to make treatment decisions subject to budget constraints in a population
setting. [155] uses clustering methods to categorize patients’ BP progression into
fixed trajectories. Personalized medicine has also found great success in oncology and
cancer treatment [156]. Personalized approaches to cancer span the full care spectrum
from risk stratification to prevention, screening, and therapy [157]. [158] develop a
partially observable Markov decision model to find personalized optimal policies for
mammography screenings. Targeted therapy based on genetic analysis has yielded
improvement over population level treatment strategies [159]. In other domains, [160]
use a stochastic model to create a personalized prediction of Glaucoma progression
and decide the time until next screening. The contribution of this work is to design
algorithms for monitoring BP from noisy observations and detecting when it has risen
above a threshold.
Bayesian methods are useful for integrating information from multiple sources of
noisy observations [161]. They have been used in many domains of science and engi-
neering, such as decision theory [162], ecology [163], and finance [164, 165]. Within
the medical decision making domain, they have explored cost effectiveness [166], in-
tegrated the findings from clinical studies [167, 168], and aided in decision support
tools for cancer care [169, 170]. Specifically in cardiology, older studies have proposed
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Bayesian approaches to classifying hypertension [171, 172, 173]. Those studies consid-
ered a fixed threshold for diagnosing hypertension and calculated positive predictive
value of multiple observations using Bayes theorem. To our knowledge, no prior study
has used Bayesian methods to construct belief of current pressure based on a longi-
tudinal model of BP change and full history of observations. Our contribution is to
provide such a model, basing our belief of current pressure on a statistically validated
disease progression model and observational noise model.
Sequential analysis is concerned with testing two hypotheses in an on-line fashion
with sequential observations. Changepoint detection is specifically concerned with
detecting a change in the state of a process subject to a tolerable limit on the risk of
false alarms [174]. Changepoint detection has been used in applications in computer
network anomaly detection [175], climate data [176], and computer vision [177]. In
the healthcare domain, changepoint detection has been used in infectious disease
surveillance [178], diagnosing speech disorders [179], and monitoring surgery outcomes
[180]. Changepoint detection has primarily been studied from an i.i.d. perspective,
that is, sequential observations are independent and identically distributed. For our
application, BP observations will be highly correlated, as pressure is serially correlated
over time. This work expands the changepoint detection literature by developing
methods for considering correlated observations.
4.3 Method
Without loss of generality, we are interested in detecting when the true VM exceeds
some threshold K. All methods in this study can be easily adapted when the detection
of interest is the VM decreasing below the threshold or leaving some interval. In
this section we first present a Bayesian belief-based changepoint detection procedure
in §4.3.1 that utilizes specific knowledge of the disease progression and observation
error, and develop computationally efficient methods. A contribution of our Bayesian
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Table 4.1: Notation in this Study
K vital measurement threshold
xt true vital measurement at time t
yt noisy vital measurement at time t
σ2 Variance of observation noise
pt probability true vital measurement at time t exceeds threshold K
St test statistic at time t




Li mixture standard deviations
n number of mixture components
fX0 the pdf of initial true BP
fXt,i the pdf of true BP Xt at time t from mixture component i
fYt,i the pdf of observation Yt at time t from mixture component i
f∆,i the pdf of change in BP per unit time from mixture component i
Naive Changepoint §4.3.2
λ allowance term for test statistic
Performance Evaluation §4.3.3
Γ time the algorithm declares a change has occurred
η0 false alarm window
τ first time the vital measurement exceeds the threshold K
` detection power window
changepoint procedure is to incorporate mixture models, which can capture a wide
range of distributions. While our analyses find this method performs well, it requires
perfect knowledge of the disease dynamics, which may not be reasonable in practice,
and in addition we are forced to rely on simulation for calibrating the decision criteria.
Motivated by these concerns, we present a naive changepoint detection algorithm in
§4.3.2. This procedure is generalizable to many VMs and requires mild assumptions
on the observation error but no explicit knowledge of the disease progression. The
notation we use in this chapter is summarized in table 4.1.
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4.3.1 Bayesian Belief Changepoint Detection
In this section we describe a Bayesian belief-based changepoint algorithm. Specifi-
cally, we model systolic BP as a continuous time, continuous space Gaussian mixture
process and develop a Bayesian filtering procedure to model our belief of current true
pressure from noisy measurements.
We model log systolic BP, denoted by Xt = log(systolic BP(t)), as a mixture of





where wi are the mixture weights, µi and Li are the mean and standard deviation of
change per unit time within each mixture component respectively, and Bt is a stan-
dard Brownian motion. Noisy observations of BP are gathered with some normally
distributed random noise:
yt = xt + εt, (4.2)
where εt ∼ N(0, σ2).
We consider the following setup. Under the null hypothesis, the patient is healthy
and the true BP is consistently below a threshold K. Alternatively, when the patient’s
blood pressure is elevated, there will be an unknown moment κ after which their BP
will be constantly above K. We need to test between these two situations based on
noisy observations. Formally, consider the following hypothesis test.
H0 : Xi < K ∀i = 1, . . . , t,
H1 : Xi < K,Xj > K ∀i = 1, . . . , κ, j = κ+ 1, . . . , t for some κ.
Since we use this procedure in an online fashion, the belief of true pressure at time
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t is dependent only on observations up until that time, and therefore
P(X1, . . . , Xt|Y1, . . . , Yt) = P(X1|Y1)P(X2|Y1, Y2) . . .P(Xt|Y1, . . . , Yt).
Our goal is to detect the changepoint κ of the true BP {Xt} as soon as possible
from a sequence of noisy observations {Yt}. We next derive the likelihood ratio based
detection procedure. For an assumed changepoint time κ = k, the log-likelihood of
the hypothesis test can be written as
log P(X1 < K, . . . , Xk < K,Xk+1 > K,Xt > K|Y1, . . . , Yt)
P(X1 < K, . . . , Xt < K|Y1, . . . , Yt)
= log
∏k
i=1 P(Xi < K|Y1, . . . , Yi)
∏t
i=k+1 P(Xi > K|Y1, . . . , Yi)∏t




log P(Xi > K|Y1, . . . , Yi)1− P(Xi > K|Y1, . . . , Yi)
, (4.3)
due to cancellation of the first k terms. Define the Bayesian log-odds ratio at time t
as
Ot = log
P(Xt > K|Y1, . . . , Yt)
1− P(Xt > K|Y1, . . . , Yt)
.
Hence, the likelihood ratio based changepoint detection procedure can be derived by
maximizing with respect to the unknown k. This leads to the following detection
procedure that stops the first time it hits a pre-specified threshold b:




Notice that the computation of the procedure amounts to computing the posterior
probability Ot at each time. Alternatively, we can recursively implement this proce-
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dure, which has a similar structure to the CUSUM:
TBayesian = inf{t ≥ 1 : St ≥ b, St = max{St−1 +Ot, 0}, S0 = 0}.
Note that the log-odds ratio under the null hypothesis tends to be negative, and
under the alternative hypothesis tends to be positive. Hence, when a patient’s true
BP is under K the test statistic will tend to stay small, and when the true BP is over
K it will tend to increase linearly.
Bayesian filtering
In the following, we describe how to compute the Bayesian belief and P(Xt >
K|Y1, . . . , Yt) in an efficient manner. Define
fX0 - the pdf of initial true BP.
fXt,i - The pdf of true BP Xt at time t from mixture component i.
fYt,i - The pdf of observation Yt at time t from mixture component i.
f∆,i - The pdf of change in BP per unit time from mixture component i.
fε - The pdf of the observation error ε.
We can compute the Bayesian posterior belief of true pressure xt given observations
y1, . . . , yt under the ith mixture component as:

























f∆,i(xj − xj−1)fYj ,i(yj|xj)
)
f∆,i(xt − xt−1) dx0dx1 . . . dxt−1
∝ fε(yt − xt)
∫ ∞
−∞
fXt−1,i(xt−1|y1, . . . , yt−1)f∆,i(xt − xt−1) dxt−1. (4.4)
We maintain this belief separately for each mixture component i. This calcula-
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Figure 4.1: Result of Bayesian filtering (Left) complete path; (Right) Zoom-in.
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tion requires low computational effort, utilizing the prior distribution and a single
integration. (4.4) says the posterior belief of this period’s true pressure is found by
integrating the prior belief and transition probability, multiplied by the likelihood
of noisy observations from this period. See Figure 4.1 for an example of this filter
operating on noisy BP observations. This figure demonstrates that even with highly
noisy observations we can create accurate belief of true BP.
The tail probability of threshold exceedance for each mixture component is easily




fXt,i(xt|y1, . . . , yt)dxt. (4.5)





Finally, the test statistic St is constructed as:




For an overview of the steps of the Bayesian changepoint algorithm, see figure 4.2
and the following algorithm:
Algorithm 1 Bayesian algorithm for BP changepoint detection
Inputs: Threshold b
Initialization: Initial belief fX0
1: Gather noisy observation yt.
2: Compute Bayesian posterior belief within each component according to (4.4).
3: Compute tail probability p̂t,i within each component with (4.5).
4: Compute aggregate tail probability p̂t with (4.6).
5: Compute test statistic St with (4.7).

































Figure 4.2: Bayesian Changepoint Detection Procedure
4.3.2 Naive CUSUM Changepoint
In this section, we develop a procedure that does not require assumptions on the
VM progression, making it relevant to a wide variety of applications. Specifically,
we assume the observations are i.i.d., which ignores the temporal correlation between
the observations. As we explain below, while this i.i.d. assumption does not hold
in practice, it provides bounds on the performance when the true VM is temporally
correlated. We further demonstrate that we achieve good performance using it on
simulated BP observations. Our only assumption in this section is that the observa-
tion noise is normally distributed with mean 0 and variance σ2. This assumption can
be easily relaxed to allow the noise to follow any distribution with known parameters.
Our goal is as follows: we are interested in detecting when the true VM is above
K, and not detecting a change when the true VM is below K− δ. Thus, the minimal
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change of interest is δ. We formally define our hypotheses:
H0 : Xi = K − δ ∀i = 1, . . . , t,
H1 : Xi = K − δ, Xj = K ∀i = 1, . . . , κ, j = κ+ 1, . . . , t for some κ.
From this setup, we can derive a naive algorithm, based on the following intuition.
When there is no change (true VM is K − δ), the probability of the observed VM
exceeding the threshold K will be small. On the other hand, when there is a change
(true VM is K), the probability that the observed BP exceeding K will be significantly
larger. Hence, we can monitor the likelihood using a cumulative sum (CUSUM)
procedure. As we will show later on, this simple algorithm has reasonably good
performance, and its theoretical performances can be well calibrated. The algorithm
is as follows:




0.5 + Φ(−δ/σ√2 )
2






where Φ() is the CDF of the standard normal distribution.
3: Compute
St = max [0, St−1 + pt − λ]. (4.9)
4: Signal a change has occurred if St ≥ b, otherwise return to step 1.
The intuition of this algorithm is based around the distribution of pt. As we
formally prove in Theorem 5 below, the expected value of pt is 0.5 under the alternate
hypothesis (true VM is K), and is Φ(−δ/σ√2 ) under the null hypothesis (true VM is
K−δ). By choosing the allowance term λ as the midpoint between these expectations,
the expectation of pt−λ is positive under the alternate hypothesis and hence St tends
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Figure 4.3: Example sample path. Upper left: true blood pressure. Upper right:
Noisy observations of blood pressure. Lower left: tail probabilities calculated from
(4.8). Lower right: Test statistic calculated from (4.9).
to linearly increase, while the expectation is negative under the null hypothesis and
St tends to stay close to 0.
For an example of these statistics with K = 140mm Hg and δ = 5mm Hg, see
figure 4.3. From observation 1 to 250, the true BP is 135 mm Hg, and the test statistic
St stays close to 0. From observations 251 to 500, the true BP is 140 mm Hg, and
the test statistic linearly increases.
The fundamental tradeoff in the design of any statistical process control problems
is between false alarms, that is, the algorithm declaring the VM above the threshold
when the true value is below the threshold, and detection power, correctly declaring
the VM above the threshold when it truly is. The typical performance evaluation
with i.i.d. samples are average run length (ARL) and detection delay (DD), the
mean number of observations until a change has been declared under the null or
alternate hypotheses, respectively. That is, ARL is the mean number of observations
until the algorithm declares a patient’s VM is above the threshold when the true
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VM is below the threshold, and DD is the mean number of observations until the
algrorithm declares a patient’s VM is above the threshold when the true VM is above
the threshold.
Theorem 5. Following the Naive algorithm, the average run length is approximately
ARL = e
δ∗c − δ∗c− 1
(δ∗)2/2 (1 + o(1)),
and the detection delay is approximately
DD = e
−δ∗c + δ∗c− 1










√√√√1/12 + Φ(−δ/σ√2 )− Φ(−δ/σ√2 )2 − 2T (−δ/σ√2 , 1√3)
2 ,
and T (·, ·) is Owen’s T function [181].
Proof. We first examine the moments of pt under the null and alternate hypotheses.












































































































The remainder of the algorithm is a traditional CUSUM approach, see for example
[182]. Since traditional CUSUM methods assume a constant variance, we define s2
as the average of the variance under the null and alternate hypotheses, similar to
as λ is defined as the average expected value. Even though the pt are not normally
distributed under either hypothesis, the CUSUM approach does not require the nor-
mality assumption.
Our computational analyses show that these approximations are quite accurate.
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Figure 4.4: Naive Changepoint Procedure ARL
See figures 4.4 and 4.5 for comparison of the true and approximate ARL and DD for
the BP problem, respectively.
When the VM dynamically progresses in a more complex form than the step
function of the hypotheses presented above, the run length statistics of Theorem 5
provide a bound on the algorithm performance. When the true VM is at least δ
below the threshold K, the average run length is at least that presented in Theorem
5, and when the true VM is greater than or equal to K, the detection delay is at most
that from the theorem. This implies the run lengths in the theorem are worst case
analyses, and the decision threshold b can be chosen using these as a conservative
measure. For an example of these statistics on simulated BP with K = 140mm Hg
and δ = 5mm Hg, see figure 4.6. As expected, at the start when true BP is below
the threshold of 140, the test statistic St stays very close to 0, despite nonzero tail
probabilities pt owing to measurement noise. When true BP approaches the threshold
around observation 150, the test statistic St begins to rise but stays low, reflecting the
weak evidence BP is above 140. When true BP experiences a sustained shift above
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Figure 4.5: Naive Changepoint Procedure DD
the threshold around observation 250 , the test statistic increases linearly.
4.3.3 Performance Evaluation
In this section we describe the criteria for evaluating decision rules under either
changepoint algorithm proposed above. When observations are i.i.d. under either
hypothesis, the ARL and DD are sensible evaluation criteria, as the process signals
with probability 1 and the ARL is finite. In the non-i.i.d. case that we face here,
this is not necessarily true - for example, consider a VM with a negative drift over
time. Then, with positive probability the process never signals, and thus the ARL is
infinite. To overcome this limitation, we consider false alarm and detection rates as
described in the following paragraphs.
To examine false alarm rates, we are interested in studying PH0(Γ < η0), where
Γ is the time the changepoint process signals and η0 is a fixed length of time, for
example 1 year. This quantity represents the probability that we give a false signal
within this length of time when the process is in control, that is, true VM is under
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Figure 4.6: Example sample path. Upper left: simulated true blood pressure. Upper
right: Noisy observations of blood pressure. Lower left: tail probabilities calculated
from (4.8). Lower right: Test statistic calculated from (4.9).
K.
To examine detection power, we are interested in PH1(Γ < τ + `|Γ > τ), where
τ is the true changepoint time. This expression is the probability that the change is
detected within ` additional observations given that it has not been detected by the
true changepoint.
Note there is a natural connection between ARL and alarm rates in the i.i.d. case
- [183] show an approximation to the probability of false alarm PH0(Γ < η0) is related
to the ARL by:
PH0(Γ < η0) ≈ 1− e−η0/ARL. (4.10)
4.4 Numerical Results
In this section we conduct a numerical study on simulated BP data to demonstrate
the efficiency of our algorithms. We simulate systolic BP of 10,000 patients for 10
years using (4.1). Patients have initial BP 135 mm Hg and we are interested in
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detecting an exceedance of threshold 140 mm Hg. Observations are gathered once
a day. The false alarm window η0 was set to 10 years.Parameter estimates for the
progression model were identical to chapter III. The observation noise was estimated
from [140], who conducted a validation of the Instant Blood Pressure Smartphone
App, a smartphone based application which measures blood pressure. They found
the application highly inaccurate, reporting a mean absolute difference between the
BP measured from this app and standard calibrated automated sphygmomanometer
reading of 12.4 for systolic BP. The results of this section may therefore be conserva-
tive, and we may expect better performance of our methods as the accuracy of the
wearable measurements improves with further development.
The ROC curve for various choices of threshold b for detection window m = 3
months, 6 months, and 1 year are seen in figures 4.7, 4.8, and 4.9 respectively. The
numerical results are seen in table 4.2. We make several observations about these
results. First, the Bayesian changepoint algorithm of §4.3.1 is quite accurate. Con-
sidering a detection window of 1 year, the AUC is 0.8887, and if we are willing to
accept a 50% chance of a false alarm within 10 years, we attain a detection rate
of 89.0%. Second, the Naive changepoint of §4.3.2 is accurate but slightly underper-
forms compared to the Bayesian algorithm in terms of AUC and detection probability
given false alarm chance of 50% across all detection windows considered (3 months,
6 months, 1 year). From the ROC curves, we observe the Bayesian approach per-
forms at least as well as the Naive approach for nearly all fixed probabilities of false
alarm. Third, the improvement in the Bayesian procedure over the Naive is greater
for smaller detection windows. The Bayesian method induces a 3.2% relative improve-
ment in AUC for 3 months detection window, but only a 0.15% relative improvement
for 1 year detection window. This indicates the Bayesian method is faster to detect
changes than the Naive method. Finally, both procedures are quite effective - the
mean true BP at time the process signals was 140.6 for the Bayesian approach and
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140.8 for the Naive approach for m = 1 year, indicating the process tends to signal
near the desired threshold.
We note that the selection of initial BP of 135 mm Hg, quite close to the threshold
of 140 mm Hg relative to the range of BP seen in patients, makes these performance
results conservative to what we would see in practice. Users with lower true BP, for
example 120 mm Hg, would produce test statistic St nearly always 0, resulting in
very few false alarms. Similarly, users with significantly elevated BP, for example
155 mm Hg, would produce tail probabilities p̂t near to 1 and would result in rapid
detection. An ancillary simulation study with the same parameters as above except
user’s initial BP sampled randomly from a data-driven distribution of population
BP levels resulted in ROC values of 0.9836 and 0.9807 for the Bayesian and Naive
algorithms, respectively. In addition, when false alarms do occur, the true VM tends
to be close to the threshold - the average true BP when a false alarm was signaled was
137.8 mm Hg for the Bayesian algorithm. This is advantageous, since the threshold
is not a firm cutoff - that is, there is likely to be benefit in recommending a patient
with true BP close to but not exceeding the threshold to a physician for preventive
care.
A baseline policy that signals the process is out of control when the weekly sample
mean exceeds the threshold K resulted in PH0 = 0.9971, PH1 = 1. This indicates
such a decision rule is extremely prone to type I errors : for example, when the true
systolic BP is 135 mm Hg, the 7-day sample mean will exceed the threshold of 140
mm Hg with probability 0.2196, indicating a type I error occurs less than every 5
weeks on average. Such a policy’s performance is unacceptable and would lead to
increased burden on the healthcare system handling these false positives.
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BiWeekly Performance Comparison, m = 90
Bayesian Log−Odds Approach
Naive Approach
Figure 4.7: ROC Changepoint Detection Performance, m = 90
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Figure 4.8: ROC Changepoint Detection Performance, m = 182
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Figure 4.9: ROC Changepoint Detection Performance, m = 365
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Table 4.2: BP Changepoint Detection Performance Statistics
Bayesian Changepoint Naive Changepoint
m = 90 days
AUC 0.6444 0.6243
PH1|PH0 = 0.5 0.6525 0.6370
m = 182 days
AUC 0.8203 0.8158
PH1|PH0 = 0.5 0.8266 0.8220
m = 365 days
AUC 0.8887 0.8873
PH1|PH0 = 0.5 0.8901 0.8893
4.5 Discussion and Conclusion
In a recent review in the American Journal of Medicine, [184] lay out a vision reengi-
neering health care delivery by 2020 to combat chronic disease. Among their recom-
mendations, they are optimistic mHealth can positively affect healthy lifestyles and
chronic disease management. The work in this chapter develops an analytics frame-
work to statistically monitor vital measurements and indicate when the probability
the measurement has exceeded some treshold is high. The changepoint detection al-
gorithms presented in this study utilize the frequent observations from mHealth to
signal the user when a sustained increase in the VM has occurred. These algorithms
are applicable to a wide variety of VMs, such as cholesterol, glucose level, and heart
rate.
The Bayesian changepoint algorithm of §4.3.1 was found to be highly accurate.
The AUC of 0.8887 for one year detection window suggests this procedure can be ef-
fective for detecting shifts in the VM above the threshold and balancing risks of type
I and type II error. The tradeoffs with this method are the added assumptions and
computational effort required. The disease progression is assumed to be known and
parameters fitted. Due to the correlation structure of the belief and test statistic, run
length approximations are not easy to obtain in an analytical form. Therefore choos-
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ing the decision threshold b to achieve some desired performance requires simulating
the process, a computational and coding burden.
The naive changepoint algorithm of §4.3.2 overcomes some of these challenges at
the cost of slightly decreased performance. The AUC of 0.8873 is slightly lower than
the Bayesian AUC, and this difference increases for smaller detection windows. This
approach is advantageous for several reasons: First, it is generalizable to any VM
we are interested in tracking. Second, the approach requires minimal assumptions.
No specific disease progression model was assumed. The only requirement is the
assumption of observation noise being normally distributed with mean zero and known
variance, but this is easily relaxed if the error follows some other known distribution
or has a nonzero mean. If the variance is unknown, it can be estimated during some
warm-up period before the process begins tracking the VM for changes. Finally, the
algorithm is computationally simple and can be computed near-instantaneously with
little formal coding.
We reiterate that the numerical results presented are conservative compared to
what we would see in practice. The initial BP of 135 mm Hg is very close to the
threshold of 140 mm Hg, resulting in increased type I errors. For example, a user
with true BP of 120 mm Hg would almost never generate a false alarm. Similarly,
a user with a highly elevated BP, for example 150 mm Hg, would almost certainly
generate an out of control signal very rapidly. In our simulations, the mean true BP
when a false signal was generated was 137.8 mm Hg, quite close to the threshold. In
this context the threshold is a soft target, so recommending a user with BP quite
close to the threshold consult their physician is still useful and not an egregious error.
Implementing these algorithms in practice will face additional challenges in trend-
ing and seasonality of the data. Blood pressure is known to follow a Circadian rhythm,
being lowest at 3:00am, rising to its highest point mid-morning, then steadily decreas-
ing throughout the remainder of the day [185]. In addition, BP varies based on season,
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temperature, and hours of daylight [186]. Therefore the mHealth observations must
be carefully considered with time stamps and adjusted with detrending methods. In
addition, the mode of observation and associated stress levels must be considered.
Even after accounting for time of day, it is reasonable to expect that, for example,
data collected from car seat sensors driving in rush hour traffic would yield higher BP
measurements due to stress than those obtained from a patient seated on the couch
watching television. With proper detrending and normalizing, measurements from
several sources could be aggregated to monitor the VM using all available data.
These results could be expanded to consider trends in individual’s BP progres-
sion as well. Keeping within the changepoint detection framework, two monitoring
statistics could be run side by side. The first is as described in this chapter, tracking
when an individual’s pressure has risen above the 140 mm Hg threshold. The second
statistic would also be a changepoint detection statistic, but focused on the trend in
pressure progression. That is, it would track how an individual’s pressure was chang-
ing over time and signal if the trend deviated from the population level trend. That
way, even if an individual’s pressure was well below the threshold, say 120 mm Hg, but
rising at an alarming rate, the individual would be notified to diagnose the problem
and consider remedial steps. These side by side statistics could track both pressure
level and change in pressure to give a more complete picture of an individual’s BP.
A second approach, deviating from the changepoint detection approach of this
chapter, is inspired by the prognostics literature for machine systems. Prognostics
aims to predict the remaining useful life of a machine with noisy observations and
historical data [187, 188]. For the BP problem, this would mean predicting when an
individual is likely to cross the 140 mm Hg threshold from their noisy BP measure-
ments. Such an approach is compatible with the framework of the mixture model
for BP progression we have presented by capturing a Bayesian belief of progression
distribution. For example, [189] proposes a method that updates the parameters of
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the mixture components the observation is most likely to come from in a Bayesian
fashion, and [190] proposes a sliding window approach to keep only the most recent
observations in memory. One proposed method could incorporate the advantages of
each approach. The first time seeing a patient, we would assume their BP progression
follows population estimates. As we begin to gather observations, our predictions of
their BP progression would incorporate these observations and forget the population
level estimates. After we have gathered sufficiently many observations (dependent
on the window size), the population estimates would have no impact and predictions
would be based solely on the individual’s observations. Such an approach would allow
us to incorporate both estimates of true pressure and estimates of BP progression to





This thesis has developed tools from probability and stochastics, optimization, statis-
tics, data science, and simulation in the operations research domain to explore issues
in blood pressure management for reducing risk of cardiovascular disease, optimizing
treatment decisions, and monitoring blood pressure from mobile health technologies.
In chapter II we improved cardiovascular disease risk prediction models by adding
a novel predictor, antecedent blood pressure, into the model. These models were cos-
ntructed and validated on the Framingham Offspring data set, the largest and longest
running longitudinal study of blood pressure and cardiovascular disease. We demon-
strated models with antecedent systolic pressure significantly outperformed models
with current systolic pressure. When antecedent pressure was included in the model,
adding current pressure did not improve the predictions, implying antecedent pres-
sure alone was a better predictor than antecedent plus current pressure. We further
demonstrated that addition of a categorical variable indicating antecedent hyperten-
sion did not improve a model with current pressure, demonstrating the importance
of complete data records. These findings were robust against other measures of blood
pressure and other baseline prediction dates. This work demonstrated the impor-
tance of a time integrated measure of blood pressure as a predictor of cardiovascular
disease.
Motivated by the results of chapter II, chapter III developed a population level
optimal policy for antihypertensive treatment decisions. The fundamental tradeoff
was dictated by the J-curve effect, implying that over aggressive treatment can lower
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blood pressure below optimal levels and increase risk. We used the Framingham
Original cohort to fit a continuous time, continuous state stochastic process to model
change in population blood pressure over time. We fit an estimate of cardiovascular
disease hazard ratio of blood pressure from a large diverse population and the ef-
fects of antihypertensive treatment from a meta-analysis of randomized control trials.
From these we derived an analytical expression of expectation and variance of T-year
hazard ratio experienced by an individual initiating an antihypertension treatment.
We used a mean-variance optimization model to pick the treatment option minimizing
risk adjusted hazard ratio. We derived systolic and diastolic thresholds for initiation
and intensification of various dosages of antihypertension treatment. In a large scale
simulation model we demonstrated the improvement of our policy over existing clin-
ical guidelines and predicted an estimated additional 15,100 premature deaths could
be averted every year. Finally, we used radial basis functions to construct approxi-
mate confidence intervals on the experienced hazard ratio under different treatment
options. These results suggest randomized control trials that could be run to examine
treatment strategies and may be used in a decision support tool.
Chapter IV developed two changepoint detection algorithms for monitoring blood
pressure from wearables and other mobile health technologies. The Bayesian method
used knowledge of disease progression and maintained a belief of current pressure. The
method was quite accurate, but faces parameter fitting and computational challenges
in practice. To overcome these challenges, a Naive changepoint detection method was
proposed that uses only the measurement error distribution. This method was simple
to implement and calibrate, and still accurate but slightly less than the Bayesian
approach. These methods demonstrate the value of measurements from mobile health
technology in monitoring vital measurements such as cholesterol, glucose level, and
pulse in the management of chronic disease.
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[59] C. Höcht, F. M. Bertera, and C. A. Taira, “Importance of blood pressure vari-
ability in the assessment of cardiovascular risk and benefits of antihypertensive
therapy”, Expert Review of Clinical Pharmacology, vol. 3, no. 5, pp. 617–621,
2010.
[60] G. Parati, J. E. Ochoa, P. Salvi, C. Lombardi, and G. Bilo, “Prognostic value
of blood pressure variability and average blood pressure levels in patients with
hypertension and diabetes”, Diabetes Care, vol. 36, no. Supplement 2, S312–
S324, 2013.
[61] D. S. Lee, J. M. Massaro, T. J. Wang, W. B. Kannel, E. J. Benjamin, S.
Kenchaiah, D. Levy, R. B. D’Agostino, and R. S. Vasan, “Antecedent blood
pressure, body mass index, and the risk of incident heart failure in later life”,
Hypertension, vol. 50, no. 5, pp. 869–876, 2007.
[62] N. H. Lung and B. Institute, “Framingham Heart Study-Offspring Data Dic-
tionary”, Tech. Rep.
[63] D. Machin, Y. B. Cheung, and M. K. Parmar, “Cox’s proportional hazards
model”, Survival Analysis: A Practical Approach, Second Edition, pp. 121–
153, 2006.
[64] M. J. Pencina and R. B. D’Agostino, “Overall C as a measure of discrimination
in survival analysis: model specific population value and confidence interval
estimation”, Statistics in Medicine, vol. 23, no. 13, pp. 2109–2123, 2004.
[65] M. J. Pencina, R. B. D’Agostino, and R. S. Vasan, “Evaluating the added
predictive ability of a new marker: from area under the ROC curve to re-
classification and beyond”, Statistics in Medicine, vol. 27, no. 2, pp. 157–172,
2008.
[66] S. S. Franklin, V. A. Lopez, N. D. Wong, G. F. Mitchell, M. G. Larson, R. S.
Vasan, and D. Levy, “Single versus combined blood pressure components and
risk for cardiovascular disease: the Framingham Heart Study”, Circulation,
vol. 119, no. 2, pp. 243–250, 2009.
[67] N. S. Beckett, R. Peters, A. E. Fletcher, J. A. Staessen, L. Liu, D. Dumitrascu,
V. Stoyanovsky, R. L. Antikainen, Y. Nikitin, C. Anderson, et al., “Treatment
of hypertension in patients 80 years of age or older”, New England Journal of
Medicine, vol. 358, no. 18, pp. 1887–1898, 2008.
125
[68] T. Ayer, O. Alagoz, and N. K. Stout, “OR forum-a POMDP approach to
personalize mammography screening decisions”, Operations Research, vol. 60,
no. 5, pp. 1019–1034, 2012.
[69] J. Zhang, B. T. Denton, H. Balasubramanian, N. D. Shah, and B. A. Inman,
“Optimization of prostate biopsy referral decisions”, Manufacturing & Service
Operations Management, vol. 14, no. 4, pp. 529–547, 2012.
[70] G. J. Schell, W. J. Marrero, M. S. Lavieri, J. B. Sussman, and R. A. Hay-
ward, “Data-driven markov decision process approximations for personalized
hypertension treatment planning”, MDM Policy & Practice, vol. 1, no. 1,
p. 2 381 468 316 674 214, 2016.
[71] O. Alagoz, L. M. Maillart, A. J. Schaefer, and M. S. Roberts, “The optimal
timing of living-donor liver transplantation”, Management Science, vol. 50,
no. 10, pp. 1420–1430, 2004.
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